{"content":"<li class=\"n-box-item date-title\" data-end=\"1574139599\" data-start=\"1574053200\" data-txt=\"Monday, December 23, 2019\">Monday, November 18, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3520312\" data-ts=\"1574121388\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520312-analysts-slash-intelsat-targets-after-auction-disappointment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analysts slash Intelsat targets after auction disappointment</a></h4><ul>   <li>Intelsat (NYSE:<a href='https://seekingalpha.com/symbol/I' title='Intelsat S.A.'>I</a>) is absorbing analyst cuts to their price targets after FCC Chairman Ajit Pai <a href=\"https://seekingalpha.com/news/3520187-intelsat-minus-17_5-percent-pai-calls-public-c-band-auction\" target=\"_blank\">punctured the company's ambitions</a> for a private auction of midband satellite spectrum.</li>    <li>That route is \"officially dead,\" JPMorgan says, while noting that there's \"still no consensus on how to get to a public auction.\" Analyst Philip Cusick will be looking to the agency to explain the legal rationale for a public auction, and cautions that if the FCC and C-Band Alliance can't \"find a path forward,\" the auction may not even make the January schedule.</li>    <li>He's keeping his Neutral rating but cutting the price target to a Street-low $9 from $22; Intelsat closed <font color=\"red\">down 40.1%</font> to $8.03 today and is <font color=\"red\">3.1% lower</font> after hours (quoting at $7.78).</li>    <li>Evercore sees less attractive risk-reward as well and slashed its price target to $11, from $38.</li>    <li>Fellow C-Band Alliance member SES (<a href='https://seekingalpha.com/symbol/SGBAF' title='SES S.A.'>OTCPK:SGBAF</a>) <font color=\"red\">fell 5.2%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3520312\" data-linked=\"Analysts slash Intelsat targets after auction disappointment\" data-tweet=\"$I $SGBAF $EUTLF - Analysts slash Intelsat targets after auction disappointment https://seekingalpha.com/news/3520312-analysts-slash-intelsat-targets-after-auction-disappointment?source=tweet\" data-url=\"https://seekingalpha.com/news/3520312-analysts-slash-intelsat-targets-after-auction-disappointment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520310\" data-ts=\"1574120464\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BILI\" target=\"_blank\">BILI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520310-bilibiliplus-2_6-on-accelerating-revenue-growth\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bilibili +2.6% on accelerating revenue growth</a></h4><ul>   <li>Bilibili (NASDAQ:<a href='https://seekingalpha.com/symbol/BILI' title='Bilibili Inc.'>BILI</a>) is <font color=\"green\">up 2.6%</font> in postmarket trading after its <a href=\"https://seekingalpha.com/news/3520306-bilibili-eps-beats-0_01-beats-revenue\" target=\"_blank\">Q3 revenues</a> grew even better than expected and the company issued strong current-quarter guidance.</li>    <li>Overall total net revenues rose 72% to 1.859B yuan (about $260.1M). Last quarter, revenues rose 50% Y/Y.</li>    <li>With cost of revenues up 71%, gross profit rose 80% to 351.3M yuan (about $49.1M).</li>    <li>Operating loss grew to 423.1M yuan (about $59.2M) from a year-ago loss of 259M yuan; net loss swelled to 405.7M yuan (about $56.8M) from a year-ago loss of 246.1M yuan. Adjusted net loss widened to 343.1M yuan from 202.7M yuan.</li>    <li>In operational metrics, average monthly active users jumped 38% to 127.9M and mobile MAUs rose 43% to 114.2M. Average daily active users rose 40% to 37.6M.</li>    <li>Revenue per MAU was 14.5 yuan (up 25%); non-game revenue per MAU was 7.2 yuan (up 100%). And average monthly paying users jumped 124% to 7.9M (up to 1.5M for mobile games).</li>    <li>Revenue by segment: Mobile games, 933.1M yuan (up 25%); Live broadcasting and Value-Added Services, 452.5M yuan (up 167%); Advertising, 247.2M yuan (up 80%); E-commerce and others, 226.1M yuan (up 703%).</li>    <li>For Q4, it's guiding to net revenues of 1.93B-1.98B yuan (about $274.7M-281.8M, above consensus for $267.7M).</li>    <li><a href=\"http://ir.bilibili.com\" target=\"_blank\">Conference call</a> to come at 8 p.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/17703095-bilibili-inc-announces-third-quarter-2019-financial-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3520310\" data-linked=\"Bilibili +2.6% on accelerating revenue growth\" data-tweet=\"$BILI - Bilibili +2.6% on accelerating revenue growth https://seekingalpha.com/news/3520310-bilibiliplus-2_6-on-accelerating-revenue-growth?source=tweet\" data-url=\"https://seekingalpha.com/news/3520310-bilibiliplus-2_6-on-accelerating-revenue-growth\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520307\" data-ts=\"1574118311\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WUBA\" target=\"_blank\">WUBA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520307-58-com-eps-beats-0_13-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">58.com EPS beats by $0.13, beats on revenue</a></h4><ul><li>58.com (NYSE:<a href='https://seekingalpha.com/symbol/WUBA' title='58.com Inc.'>WUBA</a>): Q3 Non-GAAP EPS of $0.96 <font color=\"green\">beats by $0.13</font>; GAAP EPS of $0.74 <font color=\"green\">beats by $0.13</font>.</li><li>Revenue of $602M (+17.4% Y/Y) <font color=\"green\">beats by $12.88M</font>.</li><li>Shares <font color=\"green\">+2.45%</font> AH.</li><li><a href=\"https://seekingalpha.com/pr/17703093-58-com-reports-third-quarter-2019-unaudited-financial-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3520307\" data-linked=\"58.com EPS beats by $0.13, beats on revenue\" data-tweet=\"$WUBA - 58.com EPS beats by $0.13, beats on revenue https://seekingalpha.com/news/3520307-58-com-eps-beats-0_13-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3520307-58-com-eps-beats-0_13-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:05 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520301\" data-ts=\"1574116473\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520301-okta-clvs-amc-and-dht-among-after-hour-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">OKTA, CLVS, AMC and DHT among after hour movers</a></h4><ul><li><strong>Gainers: </strong><a href='https://seekingalpha.com/symbol/CLVS' title='Clovis Oncology, Inc.'>CLVS</a> <font color=\"green\">+4.4%</font>. <a href='https://seekingalpha.com/symbol/MYOV' title='Myovant Sciences Ltd.'>MYOV</a> <font color=\"green\">+3.1%</font>. <a href='https://seekingalpha.com/symbol/WSG' title='Wanda Sports Group Company Limited'>WSG</a> <font color=\"green\">+2.6%</font>. <a href='https://seekingalpha.com/symbol/AMC' title='AMC Entertainment Holdings, Inc.'>AMC</a> <font color=\"green\">+2.1%</font>. <a href='https://seekingalpha.com/symbol/OKTA' title='Okta, Inc.'>OKTA</a> <font color=\"green\">+1.6%</font>.</li><li><strong>Losers: </strong><a href='https://seekingalpha.com/symbol/ASH' title='Ashland Global Holdings Inc.'>ASH</a> <font color=\"red\">-5.9%</font>. <a href='https://seekingalpha.com/symbol/WWD' title='Woodward, Inc.'>WWD</a> <font color=\"red\">-5.8%. </font><a href='https://seekingalpha.com/symbol/DHT' title='DHT Holdings, Inc.'>DHT</a> <font color=\"red\">-5.6%</font>. <a href='https://seekingalpha.com/symbol/KRNT' title='Kornit Digital Ltd.'>KRNT</a> <font color=\"red\">-4.9%</font>. <a href='https://seekingalpha.com/symbol/KRTX' title='Karuna Therapeutics, Inc.'>KRTX</a> <font color=\"red\">-3.1%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520301\" data-linked=\"OKTA, CLVS, AMC and DHT among after hour movers\" data-tweet=\"$CLVS $MYOV $WSG - OKTA, CLVS, AMC and DHT among after hour movers https://seekingalpha.com/news/3520301-okta-clvs-amc-and-dht-among-after-hour-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3520301-okta-clvs-amc-and-dht-among-after-hour-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520297\" data-ts=\"1574116019\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520297-s-and-p-adds-tmo-to-100-index-nowplus-3_7-on-move-to-500\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">S&amp;P adds TMO to 100 index; NOW +3.7% on move to 500</a></h4><ul>   <li>S&amp;P is making a <a href=\"https://us.spindices.com/documents/indexnews/announcements/20191118-1035566/1035566_Thermo1Service5.pdf?force_download=true\" target=\"_blank\">small shuffle to two key stock indexes</a> to account for Bristol-Myers Squibb's deal to acquire Celgene (NASDAQ:<a href='https://seekingalpha.com/symbol/CELG' title='Celgene Corporation'>CELG</a>).</li>    <li>Thermo Fisher Scientific (NYSE:<a href='https://seekingalpha.com/symbol/TMO' title='Thermo Fisher Scientific Inc.'>TMO</a>) is moving into the S&amp;P 100 to replace Celgene.</li>    <li>Meanwhile, ServiceNow (NYSE:<a href='https://seekingalpha.com/symbol/NOW' title='ServiceNow, Inc.'>NOW</a>) will take Celgene's place in the S&amp;P 500; <a href='https://seekingalpha.com/symbol/NOW' title='ServiceNow, Inc.'>NOW</a> is <font color=\"green\">up 3.7%</font> after hours.</li>    <li>The moves are effective prior to the open of trading on Thursday, Nov. 21.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3520297\" data-linked=\"S&amp;P adds TMO to 100 index; NOW +3.7% on move to 500\" data-tweet=\"$CELG $TMO $NOW - S&amp;P adds TMO to 100 index; NOW +3.7% on move to 500 https://seekingalpha.com/news/3520297-s-and-p-adds-tmo-to-100-index-nowplus-3_7-on-move-to-500?source=tweet\" data-url=\"https://seekingalpha.com/news/3520297-s-and-p-adds-tmo-to-100-index-nowplus-3_7-on-move-to-500\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520296\" data-ts=\"1574115620\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VNET\" target=\"_blank\">VNET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520296-chinas-21vianet-groupminus-3_4-on-q3-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">China&#39;s 21Vianet Group -3.4% on Q3 report</a></h4><ul>   <li>Data-center firm 21Vianet Group (NASDAQ:<a href='https://seekingalpha.com/symbol/VNET' title='21Vianet Group, Inc.'>VNET</a>) is <font color=\"red\">3.4% lower</font> postmarket after it missed revenue expectations with its <a href=\"https://seekingalpha.com/news/3520273-21vianet-group-misses-revenue\" target=\"_blank\">Q3 report</a>.</li>    <li>EBITDA rose by 11.1% to 272.5M yuan (about $38.1M), with margin of 27.8%, down from 28.2%.</li>    <li>Net revenues rose 12.7% to 981M yuan (about $137.2M), slightly slower than analyst expectations (one estimate) though it topped the high end of previous company guidance.</li>    <li>In operations, hosting MRR per cabinet jumped to 8,711 yuan from a year-ago 8,384 yuan (and last quarter's 8,663 yuan).</li>    <li>Cabinets under management were 32,116 vs. a year-ago 30,303 and last quarter's 31,111; 27,267 were in self-built data centers and 4,849 in partnered data centers. Utilization rate was 66.2%, up from last quarter's 66%.</li>    <li><a href=\"http://ir.21vianet.com\" target=\"_blank\">Conference call</a> to come at 8 p.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/17702991-21vianet-group-inc-reports-unaudited-third-quarter-2019-financial-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3520296\" data-linked=\"China&#39;s 21Vianet Group -3.4% on Q3 report\" data-tweet=\"$VNET - China&#39;s 21Vianet Group -3.4% on Q3 report https://seekingalpha.com/news/3520296-chinas-21vianet-groupminus-3_4-on-q3-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3520296-chinas-21vianet-groupminus-3_4-on-q3-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520292\" data-ts=\"1574115067\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRMT\" target=\"_blank\">CRMT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520292-americas-car-mart-eps-beats-0_19-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">America&#39;s Car-Mart EPS beats by $0.19, beats on revenue</a></h4><ul><li>America's Car-Mart (NASDAQ:<a href='https://seekingalpha.com/symbol/CRMT' title='America&#39;s Car-Mart, Inc.'>CRMT</a>): Q2 GAAP EPS of $2.00 <font color=\"green\">beats by $0.19</font>.</li><li>Revenue of $190.31M (+13.8% Y/Y) <font color=\"green\">beats by $16.84M</font>.</li><li>Shares <font color=\"green\">+3.84%</font> AH.</li><li><a href=\"https://seekingalpha.com/pr/17703046-americas-car-mart-reports-diluted-earnings-per-share-2_00-record-revenues-190-million\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3520292\" data-linked=\"America&#39;s Car-Mart EPS beats by $0.19, beats on revenue\" data-tweet=\"$CRMT - America&#39;s Car-Mart EPS beats by $0.19, beats on revenue https://seekingalpha.com/news/3520292-americas-car-mart-eps-beats-0_19-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3520292-americas-car-mart-eps-beats-0_19-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520269\" data-ts=\"1574112502\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KRTX\" target=\"_blank\">KRTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520269-karuna-therapeutics-readies-stock-offering-shares-down-7-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Karuna Therapeutics readies stock offering; shares down 7% after hours</a></h4><ul><li>On cue, Karuna Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/KRTX' title='Karuna Therapeutics, Inc.'>KRTX</a>), fresh off its five-fold <a href=\"https://seekingalpha.com/news/3520035-karuna-86-percent-premarket-positive-karxt-data\" target=\"_blank\">KarXT-stoked move</a> today, <a href=\"https://seekingalpha.com/pr/17702973-karuna-therapeutics-announces-proposed-public-offering-common-stock\" target=\"_blank\">announces</a> a public offering of 2.6M common shares. Price and terms have yet to be released.</li><li>Shares down <font color=\"red\">7%</font> after-hours.</li><li><strong>Update</strong>: The stock shrugged off early weakness on Tuesday. Shares are now exchanging hands at $130, up <font color=\"green\">35%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520269\" data-linked=\"Karuna Therapeutics readies stock offering; shares down 7% after hours\" data-tweet=\"$KRTX - Karuna Therapeutics readies stock offering; shares down 7% after hours https://seekingalpha.com/news/3520269-karuna-therapeutics-readies-stock-offering-shares-down-7-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3520269-karuna-therapeutics-readies-stock-offering-shares-down-7-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520264\" data-ts=\"1574112011\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MYOV\" target=\"_blank\">MYOV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520264-myovant-conference-call-tomorrow-on-late-stage-study-of-relugolix-in-prostate-cancer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Myovant conference call tomorrow on late-stage study of relugolix in prostate cancer</a></h4><ul><li>Myovant Sciences (NYSE:<a href='https://seekingalpha.com/symbol/MYOV' title='Myovant Sciences Ltd.'>MYOV</a>) will host a <a href=\"https://seekingalpha.com/pr/17702933-myovant-sciences-host-webcast-conference-call-8-30-m-eastern-time-tuesday-november-19-discuss\" target=\"_blank\">conference call</a> tomorrow, November 19, at 8:30 am ET to discuss results from a Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03085095?intr=relugolix&amp;lead=myovant&amp;phase=2&amp;draw=2&amp;rank=1\" target=\"_blank\">HERO</a>, evaluating oral relugolix in men with advanced prostate cancer.</li><li>If positive, the company plans to file a U.S. marketing application next quarter.</li><li>It is also developing the GnPH receptor antagonist for women with endometriosis-related pain or heavy menstrual bleeding associated with uterine fibroids.</li><li>Potential competitor: AbbVie's (NYSE:<a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a>) Orilissa (elagolix).</li><li>Shares down <font color=\"red\">2%</font> after-hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520264\" data-linked=\"Myovant conference call tomorrow on late-stage study of relugolix in prostate cancer\" data-tweet=\"$MYOV $ABBV - Myovant conference call tomorrow on late-stage study of relugolix in prostate cancer https://seekingalpha.com/news/3520264-myovant-conference-call-tomorrow-on-late-stage-study-of-relugolix-in-prostate-cancer?source=tweet\" data-url=\"https://seekingalpha.com/news/3520264-myovant-conference-call-tomorrow-on-late-stage-study-of-relugolix-in-prostate-cancer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520262\" data-ts=\"1574111919\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/I\" target=\"_blank\">I</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520262-t-supports-pais-public-midband-auction-call-iminus-40\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AT&amp;T supports Pai&#39;s public midband auction call; I -40%</a></h4><ul>   <li>AT&amp;T (NYSE:<a href='https://seekingalpha.com/symbol/T' title='AT&T Inc.'>T</a>) has <a href=\"https://www.attpublicpolicy.com/5g/att-statement-on-fcc-chairman-pais-proposal-to-unleash-c-band-spectrum-for-5g/\" target=\"_blank\">come out in favor</a> of FCC Chairman Ajit Pai's <a href=\"https://seekingalpha.com/news/3520187-intelsat-minus-17_5-percent-pai-calls-public-c-band-auction\" target=\"_blank\">call for a public auction</a> of midband satellite spectrum for use in 5G.</li>    <li>In a new public policy post, the telecom giant's Joan Marsh says the company supports the public approach, noting that C-band is an \"important 5G opportunity\" but \"a series of objectives must be met.\"</li>    <li>\"As we have previously said, any path forward must chart a course toward a fair, open and transparent auction; compensation to C-Band licensees for relinquishing rights and relocating services; proceeds for the U.S. Treasury; and a clear and reasonable transition plan that ensures broadcasters, programmers and earth station operators that their services will not be interrupted and that their relocation costs will be reimbursed,\" she says.</li>    <li>Pai's pronouncement deflated stock in Intelsat (NYSE:<a href='https://seekingalpha.com/symbol/I' title='Intelsat S.A.'>I</a>), which has been calling for a private auction to redistribute the spectrum from satellite companies to wireless providers for use in 5G deployment.</li>    <li>Intelsat stock closed the day <font color=\"red\">down 40.1%</font>. C-Band Alliance peer SES (<a href=\"http://seekingalpha.com/symbol/SGBAF\" target=\"_blank\">SGBAF</a> <font color=\"red\">-27%</font>) was also lower.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3520262\" data-linked=\"AT&amp;T supports Pai&#39;s public midband auction call; I -40%\" data-tweet=\"$I $T $I - AT&amp;T supports Pai&#39;s public midband auction call; I -40% https://seekingalpha.com/news/3520262-t-supports-pais-public-midband-auction-call-iminus-40?source=tweet\" data-url=\"https://seekingalpha.com/news/3520262-t-supports-pais-public-midband-auction-call-iminus-40\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520258\" data-ts=\"1574111682\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XLE\" target=\"_blank\">XLE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520258-energy-names-lag-on-lower-commodity-prices-for-oil-gas\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy names lag on lower commodity prices for oil, gas</a></h4><ul><li>The energy sector (<a href='https://seekingalpha.com/symbol/XLE' title='Energy Select Sector SPDR ETF'>XLE</a> <font color=\"red\">-1.3%</font>) was today's worst-performing group as oil and gas prices <a href=\"https://www.marketwatch.com/story/oil-struggles-to-build-on-last-weeks-gains-2019-11-18\" target=\"_blank\">turned sharply lower</a> amid uncertainty over the prospects for a U.S.-China trade deal.</li><li>WTI December crude closed <font color=\"red\">-1.2%</font> to $57.05/bbl and Brent settled <font color=\"red\">-1.5%</font> to $62.35/bbl; <a href=\"https://seekingalpha.com/news/3520227-nat-gas-prices-plunge-milder-weather-ample-supplies\" target=\"_blank\">losses for natural gas futures</a> were much worse.</li><li>\"Crude has become <a href=\"https://www.reuters.com/article/us-global-oil/oil-prices-fall-about-1-on-trade-talks-uncertainty-idUSKBN1XS034?il=0\" target=\"_blank\">highly reactive</a> to whichever way the wind is blowing  in the trade talks,\" says Again Capital's John Kilduff. \"When it falters, prices get punished.\"</li><li>Further headwinds came from last week\u2019s inventory data that showed a stronger-than-expected build for U.S. crude stocks, along with preliminary production figures indicating a new all-time high of 12.8M bbl/day.</li><li>Among today's biggest losers: <a href='https://seekingalpha.com/symbol/MDR' title='McDermott International, Inc.'>MDR</a> <font color=\"red\">-11.2%</font>, <a href='https://seekingalpha.com/symbol/CPE' title='Callon Petroleum Company'>CPE</a> <font color=\"red\">-9.8%</font>, <a href='https://seekingalpha.com/symbol/NE' title='Noble Corporation plc'>NE</a> <font color=\"red\">-4.7%</font>, <a href='https://seekingalpha.com/symbol/NBL' title='Noble Energy, Inc.'>NBL</a> <font color=\"red\">-4.6%</font>, <a href='https://seekingalpha.com/symbol/VAL' title='Valaris plc'>VAL</a> <font color=\"red\">-4.3%</font>, <a href='https://seekingalpha.com/symbol/HP' title='Helmerich & Payne, Inc.'>HP</a> <font color=\"red\">-4.2%</font>, <a href='https://seekingalpha.com/symbol/APA' title='Apache Corporation'>APA</a> <font color=\"red\">-3.9%</font>, <a href='https://seekingalpha.com/symbol/CLR' title='Continental Resources, Inc.'>CLR</a> <font color=\"red\">-3.7%</font>, <a href='https://seekingalpha.com/symbol/PE' title='Parsley Energy, Inc.'>PE</a> <font color=\"red\">-3.7%</font>, <a href='https://seekingalpha.com/symbol/EOG' title='EOG Resources, Inc.'>EOG</a> <font color=\"red\">-3%</font>.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>, <a href='https://seekingalpha.com/symbol/XLE' title='Energy Select Sector SPDR ETF'>XLE</a>, <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P GSCI Crude Oil Total Return Index ETN'>OIL</a>, <a href='https://seekingalpha.com/symbol/UWT' title='VelocityShares 3x Long Crude Oil ETN'>UWT</a>, <a href='https://seekingalpha.com/symbol/UCO' title='ProShares Trust II - ProShares Ultra Bloomberg Crude Oil'>UCO</a>, <a href='https://seekingalpha.com/symbol/XOP' title='SPDR S&P Oil & Gas Exploration & Production ETF'>XOP</a>, <a href='https://seekingalpha.com/symbol/VDE' title='Vanguard Energy ETF'>VDE</a>, <a href='https://seekingalpha.com/symbol/OIH' title='VanEck Vectors Oil Services ETF'>OIH</a>, <a href='https://seekingalpha.com/symbol/DWT' title='VelocityShares 3x Inverse Crude Oil ETN'>DWT</a>, <a href='https://seekingalpha.com/symbol/BNO' title='United States Brent Oil Fund, LP'>BNO</a>, <a href='https://seekingalpha.com/symbol/ERX' title='Direxion Daily Energy Bull 3x Shares ETF'>ERX</a>, <a href='https://seekingalpha.com/symbol/GUSH' title='Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 3x Shares ETF'>GUSH</a>, <a href='https://seekingalpha.com/symbol/SCO' title='ProShares UltraShort Bloomberg Crude Oil ETF'>SCO</a>, <a href='https://seekingalpha.com/symbol/BGR' title='BlackRock Energy&Resources Trust'>BGR</a>, <a href='https://seekingalpha.com/symbol/DRIP' title='Direxion Daily S&P Oil & Gas Exp. & Prod. Bear 3x Shares ETF'>DRIP</a>, <a href='https://seekingalpha.com/symbol/DBO' title='Invesco DB Oil ETF'>DBO</a>, <a href='https://seekingalpha.com/symbol/ERY' title='Direxion Daily Energy Bear 3x Shares ETF'>ERY</a>, <a href='https://seekingalpha.com/symbol/FENY' title='Fidelity Covington Trust - Fidelity MSCI Energy Index ETF'>FENY</a>, <a href='https://seekingalpha.com/symbol/DIG' title='ProShares Ultra Oil & Gas ETF'>DIG</a>, <a href='https://seekingalpha.com/symbol/NDP' title='Tortoise Energy Independence Fund'>NDP</a>, <a href='https://seekingalpha.com/symbol/DTO' title='DB Crude Oil Double Short ETN'>DTO</a>, <a href='https://seekingalpha.com/symbol/OILU' title='ProShares Trust II - ProShares UltraPro 3x Crude Oil ETF'>OILU</a>, <a href='https://seekingalpha.com/symbol/FIF' title='First Trust Energy Infrastructure Fund'>FIF</a>, <a href='https://seekingalpha.com/symbol/IYE' title='iShares U.S. Energy ETF'>IYE</a>, <a href='https://seekingalpha.com/symbol/USL' title='United States 12 Month Oil Fund, LP'>USL</a>, <a href='https://seekingalpha.com/symbol/DUG' title='ProShares UltraShort Oil & Gas ETF'>DUG</a>, <a href='https://seekingalpha.com/symbol/IEO' title='iShares U.S. Oil & Gas Exploration & Production ETF'>IEO</a>, <a href='https://seekingalpha.com/symbol/USOU' title='USCF Funds Trust - United States 3x Oil Fund'>USOU</a>, <a href='https://seekingalpha.com/symbol/OILD' title='ProShares Trust II - ProShares UltraPro 3x Short Crude Oil ETF'>OILD</a>, <a href='https://seekingalpha.com/symbol/WTIU' title='ProShares Daily 3x Long Crude ETN'>WTIU</a>, <a href='https://seekingalpha.com/symbol/CRAK' title='VanEck Vectors Oil Refiners ETF'>CRAK</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3520258\" data-linked=\"Energy names lag on lower commodity prices for oil, gas\" data-tweet=\"$XLE $MDR $CPE - Energy names lag on lower commodity prices for oil, gas https://seekingalpha.com/news/3520258-energy-names-lag-on-lower-commodity-prices-for-oil-gas?source=tweet\" data-url=\"https://seekingalpha.com/news/3520258-energy-names-lag-on-lower-commodity-prices-for-oil-gas\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>84&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520247\" data-ts=\"1574110240\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EVOK\" target=\"_blank\">EVOK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520247-evoke-pharma-up-32\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Evoke Pharma up 32%</a></h4><ul><li>Thinly traded nano cap Evoke Pharma (<a href='https://seekingalpha.com/symbol/EVOK' title='Evoke Pharma, Inc.'>EVOK</a> <font color=\"green\">+31.8%</font>) is up on an 11x surge in volume on no particular news. Last Wednesday, it <a href=\"https://seekingalpha.com/pr/17697586-evoke-pharma-granted-180-day-extension-nasdaq-regarding-minimum-bid-price\" target=\"_blank\">announced </a>that Nasdaq granted it an additional 180-day grace period to regain compliance with its $1 minimum bid price listing requirement. Shares are up <font color=\"green\">53% </font>since then.</li><li>On the working capital front, at the end of September it had $6.5M in cash and equivalents, while operations consumed $4.6M during the first three quarters of the year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520247\" data-linked=\"Evoke Pharma up 32%\" data-tweet=\"$EVOK - Evoke Pharma up 32% https://seekingalpha.com/news/3520247-evoke-pharma-up-32?source=tweet\" data-url=\"https://seekingalpha.com/news/3520247-evoke-pharma-up-32\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520245\" data-ts=\"1574109489\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MOR\" target=\"_blank\">MOR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520245-morphosys-up-7-on-advancement-of-tafasitamab-in-dlbcl\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MorphoSys up 7% on advancement of tafasitamab in DLBCL</a></h4><ul><li>Thinly traded MorphoSys AG (<a href='https://seekingalpha.com/symbol/MOR' title='MorphoSys AG'>MOR</a> <font color=\"green\">+7.3%</font>) is up on a 5x surge in volume, albeit on turnover of only 315K shares, in reaction to its <a href=\"https://seekingalpha.com/pr/17702590-morphosys-tafasitamab-b-mind-dlbcl-study-successfully-passed-futility-analysis\" target=\"_blank\">announcement </a>that its Phase 3 <a href=\"https://clinicaltrials.gov/ct2/show/NCT02763319?lead=morphosys&amp;phase=2&amp;draw=2&amp;rank=1\" target=\"_blank\">B-MIND</a> study comparing tafasitamab plus chemo agent bendamustine to Roche's (<a href='https://seekingalpha.com/symbol/RHHBY' title='Roche Holding AG'>OTCQX:RHHBY</a> <font color=\"green\">+1.4%</font>) Rituxan (rituximab) plus bendamustine in patients with relapsed/refractory diffuse large B-cell lymphoma &#40;DLBCL&#41; has passed a pre-planned interim futility analysis.</li><li>The independent Data Monitoring Committee &#40;DMC&#41; assessed the efficacy data in the overall population as well as subpopulation based on low natural killer cell count at baseline.</li><li>Aimed at increasing the study's statistical power, the DMC recommended an increase in enrollment to 450 from 330. Inclusion/exclusion criteria will remain unchanged.</li><li>Topline data are expected in in Q1 2022.</li><li>Tafasitamab is a humanized Fc-engineered monoclonal antibody that binds to a protein on the surface of B cells called CD19. The company is developing the product for the potential treatment of B cell malignancies.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520245\" data-linked=\"MorphoSys up 7% on advancement of tafasitamab in DLBCL\" data-tweet=\"$MOR $RHHBY - MorphoSys up 7% on advancement of tafasitamab in DLBCL https://seekingalpha.com/news/3520245-morphosys-up-7-on-advancement-of-tafasitamab-in-dlbcl?source=tweet\" data-url=\"https://seekingalpha.com/news/3520245-morphosys-up-7-on-advancement-of-tafasitamab-in-dlbcl\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:38 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520244\" data-ts=\"1574109371\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OC\" target=\"_blank\">OC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520244-owens-corning-upgraded-wells-after-raising-residential-insulation-prices\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Owens Corning upgraded at Wells after raising residential insulation prices</a></h4><ul><li>Owens Corning (<a href='https://seekingalpha.com/symbol/OC' title='Owens Corning'>OC</a> <font color='green'>+3.1%</font>) cruises to a 52-week high after Wells Fargo <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/19/11/14830246/owens-corning-upgraded-on-strong-insulation-roofing-potential\" target=\"_blank\">upgrades</a> shares to Outperform from Market Perform with a $77 price target, raised from $68, saying the firm's industry contacts indicate OC raised prices by 8% last week for both loose-fill and batt and role residential insulation, effective Jan. 13.</li><li>Housing starts in San Francisco, which account for ~70% of OC's U.S. residential business, could increase by 10% or more in Q4 2019 and Q1 2020, which \"provides air cover for the price hike to stick,\" says Wells analyst Truman Patterson.</li><li>Housing starts in 2020 likely will increase in the mid-to-high single-digit range, which could result in another increase in prices next year, given the industry's 90% capacity utilization levels after OC's capacity adjustments, Patterson says.</li><li>OC's average <a href=\"https://seekingalpha.com/symbol/OC/ratings/sell-side-ratings\" target=\"_blank\">Sell Side Rating</a> is Bullish, while its <a href=\"https://seekingalpha.com/symbol/OC/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> is Neutral.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520244\" data-linked=\"Owens Corning upgraded at Wells after raising residential insulation prices\" data-tweet=\"$OC - Owens Corning upgraded at Wells after raising residential insulation prices https://seekingalpha.com/news/3520244-owens-corning-upgraded-wells-after-raising-residential-insulation-prices?source=tweet\" data-url=\"https://seekingalpha.com/news/3520244-owens-corning-upgraded-wells-after-raising-residential-insulation-prices\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:36 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520240\" data-ts=\"1574108344\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PCG\" target=\"_blank\">PCG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520240-pg-and-e-loses-half-of-financial-backing-for-bankruptcy-plan\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PG&amp;E loses half of financial backing for bankruptcy plan</a></h4><ul><li>PG&amp;E (<a href='https://seekingalpha.com/symbol/PCG' title='PG&E Corporation'>PCG</a> <font color='red'>-4.9%</font>) says it now has <a href=\"https://finance.yahoo.com/news/bankrupt-pg-e-half-financing-174442052.html\" target=\"_blank\">$7.4B in commitments</a> from investors willing to help finance its restructuring plan, about half of what it had last month.</li><li>PG&amp;E replaced its previous agreements with new ones over the weekend and is planning to raise another $4.6B by Dec. 6, the utility says in a <a href=\"https://www.sec.gov/ix?doc=/Archives/edgar/data/75488/000095015719001333/form8k.htm\" target=\"_blank\">new SEC filing</a>.</li><li>Several of PG&amp;E's previous backers are missing from the new list, including multiple Fidelity funds, Soros Fund Management and the D.E. Shaw Galvanic Portfolio; PG&amp;E had more than 100 commitments last month but now has just over 20.</li><li>PG&amp;E says it believes it remains on track in securing a restructuring plan confirmed before a June 30, 2020, deadline set by California lawmakers, but Bloomberg says the disclosure could signal the company is struggling to line up financing as it works to emerge from bankruptcy.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520240\" data-linked=\"PG&amp;E loses half of financial backing for bankruptcy plan\" data-tweet=\"$PCG - PG&amp;E loses half of financial backing for bankruptcy plan https://seekingalpha.com/news/3520240-pg-and-e-loses-half-of-financial-backing-for-bankruptcy-plan?source=tweet\" data-url=\"https://seekingalpha.com/news/3520240-pg-and-e-loses-half-of-financial-backing-for-bankruptcy-plan\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520239\" data-ts=\"1574108320\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520239-spotify-down-amazon-expands-free-music-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Spotify down as Amazon expands free music offering</a></h4><ul><li>Amazon (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>) <a href=\"https://www.streetinsider.com/Corporate+News/Amazon+Music+%28AMZN%29+announces+top+playlists+and+thousands+of+stations+are+now+available+to+stream+on+even+more+devices%2C+for+free/16148925.html\" target=\"_blank\">expands</a> its free ad-supported music streaming service to customers using the Amazon Music app on iOS, Android, FireTV, and the web.</li><li>The service<a href=\"http://seekingalpha.com/news/3452075-spotify-gains-amazon-soft-launches-competitor\" target=\"_blank\"> launched in April</a>, but had previously only been available to customers using an Echo device.</li><li>Already lower on <a href=\"https://seekingalpha.com/news/3520003-tiktok-owner-launch-music-streaming-ft\" target=\"_blank\">TikTok's music</a> offering, Spotify (NYSE:<a href='https://seekingalpha.com/symbol/SPOT' title='Spotify Technology S.A.'>SPOT</a>) is now <font color=\"red\">off 4.9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520239\" data-linked=\"Spotify down as Amazon expands free music offering\" data-tweet=\"$AMZN $SPOT - Spotify down as Amazon expands free music offering https://seekingalpha.com/news/3520239-spotify-down-amazon-expands-free-music-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3520239-spotify-down-amazon-expands-free-music-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520236\" data-ts=\"1574107104\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GOLD\" target=\"_blank\">GOLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520236-barrick-gearing-for-asset-sales-while-considering-copper\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barrick gearing for more asset sales while considering more copper</a></h4><ul><li>Barrick Gold (<a href='https://seekingalpha.com/symbol/GOLD' title='Barrick Gold Corporation'>GOLD</a> <font color='green'>+1.7%</font>) is <a href=\"https://www.reuters.com/article/us-barrick-gold-asset/barrick-seeks-to-eclipse-1-5-billion-asset-sales-target-eyes-more-copper-idUSKBN1XS29H\" target=\"_blank\">eager to beat its $1.5B asset sale target</a> after <a href=\"https://seekingalpha.com/news/3520077-barrick-sell-super-pit-mine-share-750m\" target=\"_blank\">offloading its half</a> of the Super Pit gold mine in Western Australia, CEO Mark Bristow says.</li><li>The Barrick boss is not commenting on specific assets but analysts say the Lumwana copper mine in Zambia and Massawa gold mine in Senegal are likely next candidates, although neither are among the Tier 1 mines Barrick has said it will focus on.</li><li>The miner also is mulling whether and how much to extend its copper business to capitalize on growing demand for the metal in low-carbon technologies, Bristow says, noting that expanding in copper would help satisfy the growing number of investors that screen miners based on environmental, social and governance guidelines.</li><li>\"If you really believe in less carbon, lower carbon footprints and a more modern economy and lifestyle for humanity on this planet, you have to believe in copper,\" the CEO says.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520236\" data-linked=\"Barrick gearing for more asset sales while considering more copper\" data-tweet=\"$GOLD - Barrick gearing for more asset sales while considering more copper https://seekingalpha.com/news/3520236-barrick-gearing-for-asset-sales-while-considering-copper?source=tweet\" data-url=\"https://seekingalpha.com/news/3520236-barrick-gearing-for-asset-sales-while-considering-copper\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520227\" data-ts=\"1574105150\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UNG\" target=\"_blank\">UNG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520227-nat-gas-prices-plunge-on-milder-weather-ample-supplies\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nat gas prices plunge on milder weather, ample supplies</a></h4><ul><li><a href=\"https://www.wsj.com/articles/natural-gas-prices-fall-on-milder-weather-11574101989\" target=\"_blank\">Natural gas futures fall sharply</a> following predictions of moderating temperatures next week, after a frigid start to November drove prices up earlier this month; at last check, December Nymex gas (NYSEARCA:<a href='https://seekingalpha.com/symbol/UNG' title='The United States Natural Gas ETF, LP'>UNG</a>) <font color=\"red\">-4.3%</font> to $2.571/MMBtu.</li><li>\"The lack of significant cold in the upcoming period is bad news for a market dependent on continual stronger than normal heating demand to keep oversupply at bay this winter,\" Gelber &amp; Associates says.</li><li>Prices also are under pressure from strong supply, as U.S. stockpiles rose more than expected during the week ended Nov.8 to total 3.73T cf, ~15% above last year at this time and roughly flat vs. the five-year average, according to the the Energy Information Administration.</li><li>Natural gas equities are deep in the red in today's trade: <a href='https://seekingalpha.com/symbol/AR' title='Antero Resources Corporation'>AR</a> <font color=\"red\">-10.7%</font>, <a href='https://seekingalpha.com/symbol/GPOR' title='Gulfport Energy Corporation'>GPOR</a> <font color=\"red\">-10.7%</font>, <a href='https://seekingalpha.com/symbol/RRC' title='Range Resources Corporation'>RRC</a> <font color=\"red\">-10.1%</font>, <a href='https://seekingalpha.com/symbol/CHK' title='Chesapeake Energy Corporation'>CHK</a> <font color=\"red\">-8.7%</font>, <a href='https://seekingalpha.com/symbol/SWN' title='Southwestern Energy Company'>SWN</a> <font color=\"red\">-8.6%</font>, <a href='https://seekingalpha.com/symbol/EQT' title='EQT Corporation'>EQT</a> <font color=\"red\">-6.5%</font>, <a href='https://seekingalpha.com/symbol/CNX' title='CNX Resources Corporation'>CNX</a> <font color=\"red\">-5.1%</font>, <a href='https://seekingalpha.com/symbol/COG' title='Cabot Oil & Gas Corporation'>COG</a> <font color=\"red\">-4.8%</font>.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/UNG' title='The United States Natural Gas ETF, LP'>UNG</a>, <a href='https://seekingalpha.com/symbol/UGAZ' title='VelocityShares 3x Long Natural Gas ETN'>UGAZ</a>, <a href='https://seekingalpha.com/symbol/DGAZ' title='VelocityShares 3x Inverse Natural Gas ETN'>DGAZ</a>, <a href='https://seekingalpha.com/symbol/BOIL' title='ProShares Trust II - ProShares Ultra Bloomberg Natural Gas'>BOIL</a>, <a href='https://seekingalpha.com/symbol/GASL' title='Direxion Daily Natural Gas Related Bull 3x Shares ETF'>GASL</a>, <a href='https://seekingalpha.com/symbol/FCG' title='First Trust Natural Gas ETF'>FCG</a>, <a href='https://seekingalpha.com/symbol/KOLD' title='ProShares Trust II - ProShares UltraShort Bloomberg Natural Gas'>KOLD</a>, <a href='https://seekingalpha.com/symbol/GASX' title='Direxion Daily Natural Gas Related Bear 3X Shares ETF'>GASX</a>, <a href='https://seekingalpha.com/symbol/UNL' title='United States 12 Month Natural Gas Fund, LP'>UNL</a>, <a href='https://seekingalpha.com/symbol/GAZB' title='iPath Series B Bloomberg Natural Gas Subindex Total Return ETN'>GAZB</a>, <a href='https://seekingalpha.com/symbol/GAZ' title='iPath Series B Bloomberg Natural Gas Subindex Total Return ETN'>GAZ</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3520227\" data-linked=\"Nat gas prices plunge on milder weather, ample supplies\" data-tweet=\"$UNG $AR $GPOR - Nat gas prices plunge on milder weather, ample supplies https://seekingalpha.com/news/3520227-nat-gas-prices-plunge-on-milder-weather-ample-supplies?source=tweet\" data-url=\"https://seekingalpha.com/news/3520227-nat-gas-prices-plunge-on-milder-weather-ample-supplies\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>227&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520226\" data-ts=\"1574104787\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MITK\" target=\"_blank\">MITK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520226-mitek-bull-calls-pullback-an-overreaction\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mitek bull calls pullback &#39;an overreaction&#39;</a></h4><ul><li>Benchmark says Mitek Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/MITK' title='Mitek Systems, Inc.'>MITK</a>) shares look undervalued after dropping more than 40% from a March peak.</li><li>Analyst Mark Schappel calls the pullback \"an overreaction\" related to a patent infringement case against a Mitek customer.</li><li>The analyst says Mitek's current price \"seems like a \u2018going out of business\u2019 valuation in the current environment.\"</li><li>The company's fundamentals are \"sound\" and it's positioned for margin expansion, writes Schappel.</li><li>Benchmark maintains a Buy rating and trims the target from $14 to $11, saying the legal issue will remain an overhang until the next part of the litigation is resolved.</li><li>Mitek shares are <font color=\"green\">up 3.4%</font> to $7.44.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520226\" data-linked=\"Mitek bull calls pullback &#39;an overreaction&#39;\" data-tweet=\"$MITK - Mitek bull calls pullback &#39;an overreaction&#39; https://seekingalpha.com/news/3520226-mitek-bull-calls-pullback-an-overreaction?source=tweet\" data-url=\"https://seekingalpha.com/news/3520226-mitek-bull-calls-pullback-an-overreaction\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520225\" data-ts=\"1574104661\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MCD\" target=\"_blank\">MCD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520225-new-mcdonalds-ceo-rallies-troops\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New McDonald&#39;s CEO rallies the troops</a></h4><ul> <li>McDonald's (<a href='https://seekingalpha.com/symbol/MCD' title='McDonald&#39;s Corporation'>MCD</a> <font color='green'>+0.2%</font>) CEO Chris Kempczinski states in a <a href=\"https://www.cnbc.com/2019/11/18/mcdonalds-new-ceo-invites-employee-feedback-stands-by-companys-growth-plan.html\" target=\"_blank\">message</a> to employees that he feels the company is on the right path to sharpen its 2020 execution plans. The exec sent the company-wide email after he spent last week meeting with McDonald's senior leadership team and managing directors from across global markets.</li> <li>Kempczinski says the meetings reaffirmed his confidence in the leadership in place, as well as the relevance and strength of the Velocity Growth Plan.</li> <li>Shares of MCD are up 9.5% YTD, despite stumbling over the last few weeks.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3520225\" data-linked=\"New McDonald&#39;s CEO rallies the troops\" data-tweet=\"$MCD - New McDonald&#39;s CEO rallies the troops https://seekingalpha.com/news/3520225-new-mcdonalds-ceo-rallies-troops?source=tweet\" data-url=\"https://seekingalpha.com/news/3520225-new-mcdonalds-ceo-rallies-troops\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520223\" data-ts=\"1574103894\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520223-stabilis-energy-and-yuma-energy-among-energy-materials-gainers-trilogy-metals-and-range\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stabilis Energy and Yuma Energy among Energy/Materials gainers; Trilogy Metals  and Range Resources among losers</a></h4><ul><li><b>Gainers: </b>Stabilis Energy (<a href='https://seekingalpha.com/symbol/SLNG' title='Stabilis Energy, Inc.'>OTC:SLNG</a>) <font color=\"green\">+19%</font>. Yuma Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/YUMA' title='Yuma Energy, Inc.'>YUMA</a>) <font color=\"green\">+7%</font>. Mammoth Energy Services (NASDAQ:<a href='https://seekingalpha.com/symbol/TUSK' title='Mammoth Energy Services, Inc.'>TUSK</a>) <font color=\"green\">+7%</font>. SilverCrest Metals (NYSEMKT:<a href='https://seekingalpha.com/symbol/SILV' title='SilverCrest Metals Inc.'>SILV</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers: </b>Trilogy Metals (NYSEMKT:<a href='https://seekingalpha.com/symbol/TMQ' title='Trilogy Metals Inc.'>TMQ</a>) <font color=\"red\">-11%</font>. Range Resources (NYSE:<a href='https://seekingalpha.com/symbol/RRC' title='Range Resources Corporation'>RRC</a>) <font color=\"red\">-11%</font>. Centrus Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/LEU' title='Centrus Energy Corp.'>LEU</a>) <font color=\"red\">-10%</font>. Antero Resources (NYSE:<a href='https://seekingalpha.com/symbol/AR' title='Antero Resources Corporation'>AR</a>) <font color=\"red\">-10%</font>. Gulfport Energy (NASDAQ:<a href='https://seekingalpha.com/symbol/GPOR' title='Gulfport Energy Corporation'>GPOR</a>) <font color=\"red\">-9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520223\" data-linked=\"Stabilis Energy and Yuma Energy among Energy/Materials gainers; Trilogy Metals  and Range Resources among losers\" data-tweet=\"$SLNG $YUMA $TUSK - Stabilis Energy and Yuma Energy among Energy/Materials gainers; Trilogy Metals and Range Resources among losers https://seekingalpha.com/news/3520223-stabilis-energy-and-yuma-energy-among-energy-materials-gainers-trilogy-metals-and-range?source=tweet\" data-url=\"https://seekingalpha.com/news/3520223-stabilis-energy-and-yuma-energy-among-energy-materials-gainers-trilogy-metals-and-range\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520222\" data-ts=\"1574103769\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FTNT\" target=\"_blank\">FTNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520222-fortinetplus-2-after-investor-day-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fortinet +2% after investor day guidance</a></h4><ul><li>During its investor day event, Fortinet (NASDAQ:<a href='https://seekingalpha.com/symbol/FTNT' title='Fortinet, Inc.'>FTNT</a>) reaffirms its Q4 guidance with EPS of $0.69-0.71, GAAP revenue of $595-610M, and gross margin of 75.5-76.5%.</li><li>The 2020-22 outlook sees billings and GAAP revenue growth of over 15% and operating margin of +25%.</li><li>Read the full investor presentation <a href=\"https://investor.fortinet.com/static-files/d13b9e41-7996-44a5-8e0d-ab87784bc72b\" target=\"_blank\">here</a>.</li><li>Fortinet shares are <font color=\"green\">up 2.4%</font> to $103.96.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520222\" data-linked=\"Fortinet +2% after investor day guidance\" data-tweet=\"$FTNT - Fortinet +2% after investor day guidance https://seekingalpha.com/news/3520222-fortinetplus-2-after-investor-day-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3520222-fortinetplus-2-after-investor-day-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520220\" data-ts=\"1574103336\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PGR\" target=\"_blank\">PGR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520220-goldman-pulls-progressive-from-conviction-buy-list-sharesminus-2_7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Goldman pulls Progressive from Conviction Buy list; shares -2.7%</a></h4><ul><li>Progressive (NYSE:<a href='https://seekingalpha.com/symbol/PGR' title='The Progressive Corporation'>PGR</a>) <font color=\"red\">slides 2.7%</font> after Goldman Sachs analyst Yaron Kinar cut the stock to neutral from buy and removes PGR from Goldman's Americas Conviction List.</li><li>The analyst sees core margins narrowing more than previously expected.</li><li>Note PGR lacks a near-term catalyst and expects 2020-'21 consensus estimates to decline as the insurer focuses on revenue more than maintaining core margins, Kinar writes.</li><li>Kinar's new rating agrees with Quant rating of<a href=\"https://seekingalpha.com/symbol/PGR/ratings/quant-ratings\" target=\"_blank\"> Neutral</a>; before this action, the Sell-Side average rating was<a href=\"https://seekingalpha.com/symbol/PGR/ratings/sell-side-ratings\" target=\"_blank\"> Bullish</a> (8 Very Bullish, 3 Bullish, 9 Neutral, 1 Bearish).</li></ul><div class=\"tiny-share-widget\" data-id=\"3520220\" data-linked=\"Goldman pulls Progressive from Conviction Buy list; shares -2.7%\" data-tweet=\"$PGR - Goldman pulls Progressive from Conviction Buy list; shares -2.7% https://seekingalpha.com/news/3520220-goldman-pulls-progressive-from-conviction-buy-list-sharesminus-2_7?source=tweet\" data-url=\"https://seekingalpha.com/news/3520220-goldman-pulls-progressive-from-conviction-buy-list-sharesminus-2_7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520218\" data-ts=\"1574102475\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520218-juno-owner-partners-lyft-sharesplus-4_7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Juno owner partners with Lyft; shares +4.7%</a></h4><ul><li>Gett <a href=\"https://www.prnewswire.com/news-releases/gett-announces-closure-of-juno-and-strategic-partnership-with-lyft-300960004.html\" target=\"_blank\">closes</a> its New York-based Juno, effective today. The company also announces a strategic partnership with Lyft (NASDAQ:<a href='https://seekingalpha.com/symbol/LYFT' title='Lyft, Inc.'>LYFT</a>) to provide Gett's corporate clients with rides starting next year.</li><li>Gett says it serves over 15,000 companies for corporate transportation, including a third of the Fortune 500.</li><li>Lyft shares are <font color=\"green\">up 4.7%</font> to $45.08.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520218\" data-linked=\"Juno owner partners with Lyft; shares +4.7%\" data-tweet=\"$LYFT - Juno owner partners with Lyft; shares +4.7% https://seekingalpha.com/news/3520218-juno-owner-partners-lyft-sharesplus-4_7?source=tweet\" data-url=\"https://seekingalpha.com/news/3520218-juno-owner-partners-lyft-sharesplus-4_7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520216\" data-ts=\"1574101902\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WHR\" target=\"_blank\">WHR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520216-whirlpool-stumbles-after-shipments-data-release\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Whirlpool stumbles after shipments data release</a></h4><ul> <li>Whirlpool (<a href='https://seekingalpha.com/symbol/WHR' title='Whirlpool Corporation'>WHR</a> <font color='red'>-0.9%</font>) dips after monthly <a href=\"https://www.aham.org/AHAM/What_We_Do/Industry_Data___Research/AHAM/What_We_Do/Industry_Data__Research.aspx?hkey=9cbf5066-987b-4cc5-8928-2f3a0da93e33\" target=\"_blank\">data</a> from the Association of Home Manufacturers comes in weak.</li> <li>AHAM reports total appliance shipments fell 11.9% in October and AHAM 6 appliance shipments were down 12.1%.</li><li>Shares of Whirlpool were in positive territory earlier in the day.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3520216\" data-linked=\"Whirlpool stumbles after shipments data release\" data-tweet=\"$WHR - Whirlpool stumbles after shipments data release https://seekingalpha.com/news/3520216-whirlpool-stumbles-after-shipments-data-release?source=tweet\" data-url=\"https://seekingalpha.com/news/3520216-whirlpool-stumbles-after-shipments-data-release\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520204\" data-ts=\"1574100690\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BBIO\" target=\"_blank\">BBIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520204-eidos-up-13-on-sustained-benefit-of-ag10-in-attr-cm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eidos up 13% on sustained benefit of AG10 in ATTR-CM</a></h4><ul><li>Eidos Therapeutics (<a href='https://seekingalpha.com/symbol/EIDX' title='Eidos Therapeutics, Inc.'>EIDX</a> <font color=\"green\">+13%</font>) <a href=\"https://seekingalpha.com/pr/17701559-bridgebio-eidos-present-data-phase-2-open-label-extension-suggesting-long-term-tolerability\" target=\"_blank\">announces </a>positive data from the ongoing <a href=\"https://clinicaltrials.gov/ct2/show/NCT03536767?lead=eidos&amp;phase=12&amp;draw=2&amp;rank=2\" target=\"_blank\">open-label extension</a> &#40;OLE&#41; of a <a href=\"https://clinicaltrials.gov/ct2/show/NCT03458130?lead=eidos&amp;phase=12&amp;draw=2&amp;rank=3\" target=\"_blank\">Phase 2 study</a> evaluating AG10 in patients with symptomatic transthyretin &#40;TTR&#41; amyloidosis cardiomyopathy (ATTR-CM). The results were presented at the American Heart Association Scientific Sessions in Philadelphia.</li><li>Near-complete TTR stabilization was observed in patients receiving 800 mg of AG10 twice daily during the OLE and followed for a median of 65 weeks since Phase 2 initiation. Lower mortality rates and cardiovascular-related hospitalizations were observed in AG10 patients compared to those who received placebo in the main trial. Cardiac biomarkers and echocardiographic measures were stable in AG10 patients in the OLE.</li><li>A Phase 3 trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03860935?lead=eidos&amp;phase=12&amp;draw=2&amp;rank=1\" target=\"_blank\">ATTRibute-CM</a>, is in process.</li><li>Related ticker: BridgeBio Pharma (<a href='https://seekingalpha.com/symbol/BBIO' title='BridgeBio Pharma, Inc.'>BBIO</a> <font color=\"green\">+4.7%</font>).</li></ul><div class=\"tiny-share-widget\" data-id=\"3520204\" data-linked=\"Eidos up 13% on sustained benefit of AG10 in ATTR-CM\" data-tweet=\"$BBIO $EIDX $EIDX - Eidos up 13% on sustained benefit of AG10 in ATTR-CM https://seekingalpha.com/news/3520204-eidos-up-13-on-sustained-benefit-of-ag10-in-attr-cm?source=tweet\" data-url=\"https://seekingalpha.com/news/3520204-eidos-up-13-on-sustained-benefit-of-ag10-in-attr-cm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:11 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520211\" data-ts=\"1574100447\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520211-sls-cpst-i-qd-and-cgix-among-midday-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SLS, CPST, I, QD and CGIX among midday movers</a></h4><ul><li><strong>Gainers: </strong>Karuna Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/KRTX' title='Karuna Therapeutics, Inc.'>KRTX</a>) <font color=\"green\">+282%</font></li><li>Hermitage Offshore Services (NYSE:<a href='https://seekingalpha.com/symbol/PSV' title='Hermitage Offshore Services Ltd.'>PSV</a>) <font color=\"green\">+50%</font>.</li><li>Eltek (NASDAQ:<a href='https://seekingalpha.com/symbol/ELTK' title='Eltek Ltd.'>ELTK</a>) <font color=\"green\">+30%</font>.</li><li>Capstone Turbine Corporation (NASDAQ:<a href='https://seekingalpha.com/symbol/CPST' title='Capstone Turbine Corporation'>CPST</a>) <font color=\"green\">+27%</font>.</li><li>BiomX (NYSEMKT:<a href='https://seekingalpha.com/symbol/PHGE' title='BiomX Inc.'>PHGE</a>) <font color=\"green\">+23%</font>.</li><li>Cellcom Israel (NYSE:<a href='https://seekingalpha.com/symbol/CEL' title='Cellcom Israel Ltd.'>CEL</a>) <font color=\"green\">+22%</font>.</li><li>Stabilis Energy (<a href='https://seekingalpha.com/symbol/SLNG' title='Stabilis Energy, Inc.'>OTC:SLNG</a>) <font color=\"green\">+19%</font>.</li><li>Matinas BioPharma Holdings (NYSEMKT:<a href='https://seekingalpha.com/symbol/MTNB' title='Matinas BioPharma Holdings, Inc.'>MTNB</a>) <font color=\"green\">+19%</font>.</li><li>DarioHealth (NASDAQ:<a href='https://seekingalpha.com/symbol/DRIO' title='DarioHealth Corp.'>DRIO</a>) <font color=\"green\">+19%</font>.</li><li>RAVE Restaurant Group (NASDAQ:<a href='https://seekingalpha.com/symbol/RAVE' title='RAVE Restaurant Group, Inc.'>RAVE</a>) <font color=\"green\">+19%</font>.</li> <li><strong>Losers: </strong>Anchiano Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ANCN' title='Anchiano Therapeutics Ltd'>ANCN</a>) <font color=\"red\">-22%</font>.</li><li>Qudian (NYSE:<a href='https://seekingalpha.com/symbol/QD' title='Qudian Inc.'>QD</a>) <font color=\"red\">-21%</font>.</li><li>SELLAS Life Sciences Group (NASDAQ:<a href='https://seekingalpha.com/symbol/SLS' title='SELLAS Life Sciences Group, Inc.'>SLS</a>) <font color=\"red\">-21%</font>.</li><li>Intelsat S.A. (NYSE:<a href='https://seekingalpha.com/symbol/I' title='Intelsat S.A.'>I</a>) <font color=\"red\">-16%</font>.</li><li>Farmmi (NASDAQ:<a href='https://seekingalpha.com/symbol/FAMI' title='Farmmi, Inc.'>FAMI</a>) <font color=\"red\">-16%</font>.</li><li>Cancer Genetics (NASDAQ:<a href='https://seekingalpha.com/symbol/CGIX' title='Cancer Genetics, Inc.'>CGIX</a>) <font color=\"red\">-14%</font>.</li><li>RAPT Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/RAPT' title='RAPT Therapeutics, Inc.'>RAPT</a>) <font color=\"red\">-13%</font>.</li><li>Cabot Microelectronics (NASDAQ:<a href='https://seekingalpha.com/symbol/CCMP' title='Cabot Microelectronics Corporation'>CCMP</a>) <font color=\"red\">-13%</font>.</li><li>Akerna (NASDAQ:<a href='https://seekingalpha.com/symbol/KERN' title='Akerna Corp.'>KERN</a>) <font color=\"red\">-13%</font>.</li><li>Wanda Sports Group Company (NASDAQ:<a href='https://seekingalpha.com/symbol/WSG' title='Wanda Sports Group Company Limited'>WSG</a>) <font color=\"red\">-12%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3520211\" data-linked=\"SLS, CPST, I, QD and CGIX among midday movers\" data-tweet=\"$KRTX $PSV $ELTK - SLS, CPST, I, QD and CGIX among midday movers https://seekingalpha.com/news/3520211-sls-cpst-i-qd-and-cgix-among-midday-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3520211-sls-cpst-i-qd-and-cgix-among-midday-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:07 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520208\" data-ts=\"1574100249\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520208-capstone-turbine-leads-industrial-gainers-tutor-perini-and-briggs-stratton-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Capstone Turbine leads industrial gainers; Tutor Perini and Briggs &amp; Stratton among losers</a></h4><ul><li><b>Gainers: </b>Capstone Turbine (NASDAQ:<a href='https://seekingalpha.com/symbol/CPST' title='Capstone Turbine Corporation'>CPST</a>) <font color=\"green\">+29%</font>. Air Industries (NYSEMKT:<a href='https://seekingalpha.com/symbol/AIRI' title='Air Industries Group'>AIRI</a>) <font color=\"green\">+11%</font>. Charah Solutions (NYSE:<a href='https://seekingalpha.com/symbol/CHRA' title='Charah Solutions, Inc.'>CHRA</a>) <font color=\"green\">+8%</font>. Huitao Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/HHT' title='Huitao Technology Co.'>HHT</a>) <font color=\"green\">+6%</font>. The LGL Group (NYSEMKT:<a href='https://seekingalpha.com/symbol/LGL' title='The LGL Group, Inc.'>LGL</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers: </b>RAPT Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/RAPT' title='RAPT Therapeutics, Inc.'>RAPT</a>) <font color=\"red\">-13%</font>. Astrotech (NASDAQ:<a href='https://seekingalpha.com/symbol/ASTC' title='Astrotech Corporation'>ASTC</a>) <font color=\"red\">-10%</font>. NF Energy Saving (NASDAQ:<a href='https://seekingalpha.com/symbol/BIMI' title='NF Energy Saving Corporation'>BIMI</a>) <font color=\"red\">-8%</font>. Tutor Perini (NYSE:<a href='https://seekingalpha.com/symbol/TPC' title='Tutor Perini Corporation'>TPC</a>) <font color=\"red\">-8%</font>. Briggs &amp; Stratton (NYSE:<a href='https://seekingalpha.com/symbol/BGG' title='Briggs & Stratton Corporation'>BGG</a>) <font color=\"red\">-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520208\" data-linked=\"Capstone Turbine leads industrial gainers; Tutor Perini and Briggs &amp; Stratton among losers\" data-tweet=\"$CPST $AIRI $CHRA - Capstone Turbine leads industrial gainers; Tutor Perini and Briggs &amp; Stratton among losers https://seekingalpha.com/news/3520208-capstone-turbine-leads-industrial-gainers-tutor-perini-and-briggs-stratton-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3520208-capstone-turbine-leads-industrial-gainers-tutor-perini-and-briggs-stratton-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520207\" data-ts=\"1574100230\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520207-cart-leads-financial-gainers-aihs-and-mdly-only-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CART leads financial gainers; AIHS and MDLY the only losers</a></h4><ul><li><b>Gainers:</b> Carolina Trust BancShares (NASDAQ:<a href='https://seekingalpha.com/symbol/CART' title='Carolina Trust BancShares, Inc.'>CART</a>) <font color=\"green\">+10%</font>. Carolina Financial (NASDAQ:<a href='https://seekingalpha.com/symbol/CARO' title='Carolina Financial Corporation'>CARO</a>) <font color=\"green\">+8%</font>. Arcturus Therapeutics Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/ARCT' title='Arcturus Therapeutics Holdings Inc.'>ARCT</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers:</b> Senmiao Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/AIHS' title='Senmiao Technology Limited'>AIHS</a>) <font color=\"red\">-11%</font>. Medley Management (NYSE:<a href='https://seekingalpha.com/symbol/MDLY' title='Medley Management Inc.'>MDLY</a>) <font color=\"red\">-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520207\" data-linked=\"CART leads financial gainers; AIHS and MDLY the only losers\" data-tweet=\"$CART $CARO $ARCT - CART leads financial gainers; AIHS and MDLY the only losers https://seekingalpha.com/news/3520207-cart-leads-financial-gainers-aihs-and-mdly-only-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3520207-cart-leads-financial-gainers-aihs-and-mdly-only-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:03 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520194\" data-ts=\"1574099049\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVEO\" target=\"_blank\">AVEO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520194-aveo-pharma-up-4-on-advancement-of-tivozanib\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aveo Pharma up 4% on advancement of tivozanib</a></h4><ul><li>AVEO Pharmaceuticals (<a href='https://seekingalpha.com/symbol/AVEO' title='AVEO Pharmaceuticals, Inc.'>AVEO</a> <font color=\"green\">+3.5%</font>) is up on below-average volume on the heels of <a href=\"https://seekingalpha.com/pr/17701751-aveo-announces-presentation-updated-os-subgroup-data-phase-3-tivominus-3-trial-tivozanib\" target=\"_blank\">updated survival and subgroup data</a> from the Phase 3 <a href=\"https://clinicaltrials.gov/ct2/show/NCT02627963?intr=tivozanib&amp;lead=aveo+pharmaceuticals&amp;phase=2&amp;draw=2&amp;rank=1\" target=\"_blank\">TIVO-3</a> study comparing Fotivda (tivozanib) to Bayer's (<a href='https://seekingalpha.com/symbol/BAYRY' title='Bayer Aktiengesellschaft'>OTCPK:BAYRY</a> <font color=\"green\">+0.3%</font>) Nexavar (sorafenib) in patients with refractory advanced renal cell carcinoma &#40;RCC&#41;. The results were presented at the International Kidney Cancer Symposium in Miami.</li><li>Interim overall survival &#40;OS&#41; hazard ratio was 0.99 in the intent-to-treat population.</li><li>Tivozanib demonstrated superiority over sorafenib as measured by median progression-free survival &#40;PFS&#41; and overall response rate &#40;ORR&#41; in two subpopulations of patients who previously received a checkpoint inhibitor and VEGF TKI therapy or two prior VEGF TKIs.</li><li>As of the August 15 data cutoff, median OS in tivozanib arm was 16.4 months versus 19.7 months for sorafenib.</li><li>No new safety signals were reported.</li><li>The company plans to submit an update to the statistical analysis plan to the FDA which will allow the final OS analysis to be done. A marketing application will follow in Q1 2020. By mutual agreement, if the OS hazard ratio is above 1.00, the company will withdraw the application. The agency indicated that an advisory committee meeting will likely be needed to review the final data package.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520194\" data-linked=\"Aveo Pharma up 4% on advancement of tivozanib\" data-tweet=\"$AVEO $AVEO $BAYRY - Aveo Pharma up 4% on advancement of tivozanib https://seekingalpha.com/news/3520194-aveo-pharma-up-4-on-advancement-of-tivozanib?source=tweet\" data-url=\"https://seekingalpha.com/news/3520194-aveo-pharma-up-4-on-advancement-of-tivozanib\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520199\" data-ts=\"1574098564\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TNK\" target=\"_blank\">TNK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520199-teekay-tankers-upped-two-notches-to-buy-baml\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Teekay Tankers upped two notches to Buy at BAML</a></h4><ul><li>Teekay Tankers (<a href='https://seekingalpha.com/symbol/TNK' title='Teekay Tankers Ltd.'>TNK</a> <font color=\"red\">-0.8%</font>) trades lower despite winning a <a href=\"https://thefly.com/thestreet/realmoney/index.php/TNKid2995203/TNK-Teekay-Tankers-upgraded-two-notches-to-Buy-from-Underperform-at-BofAMerrill\" target=\"_blank\">double-upgrade to Buy</a> from Underperform with a $3 price target, raised from $2, at BofA Merrill Lynch.</li><li>Despite TNK's 83% run-up since October, BAML analyst Ken Hoexter believes the stock can \"re-rate higher\" with crude tanker markets currently in the \"early stages of a robust recovery\" and given the company's \"attractive operating leverage\" to rate inflections.</li><li>Hoexter thinks TNK's mid-sized vessels will benefit from an improving crude tanker market, with current tanker demand expected to rise by 6% in FY 2020. that should \"materially outpace muted fleet supply growth of 1%-2%.\"</li><li>TNK's average <a href=\"https://seekingalpha.com/symbol/TNK/ratings/sell-side-ratings\" target=\"_blank\">Sell Side Rating</a> and <a href=\"https://seekingalpha.com/symbol/TNK/ratings/author-ratings#filter=all\" target=\"_blank\">Seeking Alpha Authors Rating</a> both are Very Bullish, while its <a href=\"https://seekingalpha.com/symbol/TNK/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> is Neutral.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520199\" data-linked=\"Teekay Tankers upped two notches to Buy at BAML\" data-tweet=\"$TNK - Teekay Tankers upped two notches to Buy at BAML https://seekingalpha.com/news/3520199-teekay-tankers-upped-two-notches-to-buy-baml?source=tweet\" data-url=\"https://seekingalpha.com/news/3520199-teekay-tankers-upped-two-notches-to-buy-baml\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520191\" data-ts=\"1574096661\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMRN\" target=\"_blank\">AMRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520191-amarin-down-6-after-vascepa-stoked-run-up-potential-lack-of-effect-in-plaque-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amarin down 6% after Vascepa-stoked run-up; potential lack of effect in plaque study</a></h4><ul><li>Amarin (<a href='https://seekingalpha.com/symbol/AMRN' title='Amarin Corporation plc'>AMRN</a> <font color=\"red\">-5.5%</font>) slips on more than double normal volume as investors take some money off the table after last week's <font color=\"green\">37%</font> rally related to the positive Ad Com vote on a CV benefit claim for Vascepa (icosapent ethyl).</li><li>Another item that may be having an effect on the selling is results from the 80-subject <a href=\"https://clinicaltrials.gov/ct2/show/NCT02926027?intr=icosapent+ethyl&amp;titles=evaporate&amp;draw=2&amp;rank=1\" target=\"_blank\">EVAPORATE</a> study that evaluated the effect of Vascepa on reducing coronary plaque in patients with elevated (200-499 mg/dL) triglycerides. The results showed no significant separation from placebo on the progression rates of plaque at month 18, the primary endpoint (<a href=\"https://twitter.com/adamfeuerstein/media\" target=\"_blank\">presentation slides</a> published by STAT News), although a positive effect was noted on certain secondary endpoints.</li><li><strong>Update</strong>: Apparently the data are preliminary at month 9.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520191\" data-linked=\"Amarin down 6% after Vascepa-stoked run-up; potential lack of effect in plaque study\" data-tweet=\"$AMRN - Amarin down 6% after Vascepa-stoked run-up; potential lack of effect in plaque study https://seekingalpha.com/news/3520191-amarin-down-6-after-vascepa-stoked-run-up-potential-lack-of-effect-in-plaque-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3520191-amarin-down-6-after-vascepa-stoked-run-up-potential-lack-of-effect-in-plaque-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>83&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520189\" data-ts=\"1574096380\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520189-peloton-interactive-among-consumer-gainers-pyxus-international-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Peloton Interactive among consumer gainers; Pyxus International among losers</a></h4><ul><li><b>Gainers: </b>China Automotive Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/CAAS' title='China Automotive Systems, Inc.'>CAAS</a>) <font color=\"green\">+10%</font>. Vapotherm (NYSE:<a href='https://seekingalpha.com/symbol/VAPO' title='Vapotherm, Inc.'>VAPO</a>) <font color=\"green\">+7%</font>. Peloton Interactive (NASDAQ:<a href='https://seekingalpha.com/symbol/PTON' title='Peloton Interactive, Inc.'>PTON</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers: </b>Farmmi (NASDAQ:<a href='https://seekingalpha.com/symbol/FAMI' title='Farmmi, Inc.'>FAMI</a>) <font color=\"red\">-15%</font>. Arcimoto (NASDAQ:<a href='https://seekingalpha.com/symbol/FUV' title='Arcimoto, Inc.'>FUV</a>) <font color=\"red\">-9%</font>. Pyxus International (NYSE:<a href='https://seekingalpha.com/symbol/PYX' title='Pyxus International, Inc.'>PYX</a>) <font color=\"red\">-8%</font>. Xcel Brands (NASDAQ:<a href='https://seekingalpha.com/symbol/XELB' title='Xcel Brands, Inc.'>XELB</a>) <font color=\"red\">-7%</font>. Village Farms International (NASDAQ:<a href='https://seekingalpha.com/symbol/VFF' title='Village Farms International, Inc.'>VFF</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520189\" data-linked=\"Peloton Interactive among consumer gainers; Pyxus International among losers\" data-tweet=\"$CAAS $VAPO $PTON - Peloton Interactive among consumer gainers; Pyxus International among losers https://seekingalpha.com/news/3520189-peloton-interactive-among-consumer-gainers-pyxus-international-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3520189-peloton-interactive-among-consumer-gainers-pyxus-international-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520187\" data-ts=\"1574096026\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/I\" target=\"_blank\">I</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520187-intelsatminus-17_5-pai-calls-for-public-c-band-auction\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intelsat -17.5% as Pai calls for public C-band auction</a></h4><ul>   <li>Intelsat (NYSE:<a href='https://seekingalpha.com/symbol/I' title='Intelsat S.A.'>I</a>) has <font color=\"red\">slid 17.5%</font>, triggering a circuit breaker, after FCC Chairman Ajit Pai says he now is calling for a public auction of C-band airwaves.</li>    <li>That is a nod to pressure from lawmakers for a public auction vs. the private auction that Intelsat and its C-Band Alliance had supported.</li>    <li>\"After much deliberation and a thorough review of the extensive record, I've concluded that the best way to advance these principles is <a href=\"https://twitter.com/AjitPaiFCC/status/1196469021358592000\" target=\"_blank\">through a public auction</a> of 280 megahertz of the C-band conducted by the @FCC's excellent staff,\" Pai says.</li>    <li>That's in support, he says, of four principles: freeing up significant spectrum for 5G; doing it quickly; generating federal revenue; and ensuring continuity of current service.</li><li>On watch: related firms SES (<a href='https://seekingalpha.com/symbol/SGBAF' title='SES S.A.'>OTCPK:SGBAF</a>) and Eutelsat (<a href='https://seekingalpha.com/symbol/EUTLY' title='Eutelsat Communications ADR'>OTCPK:EUTLY</a>).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3520187\" data-linked=\"Intelsat -17.5% as Pai calls for public C-band auction\" data-tweet=\"$I $I $SGBAF - Intelsat -17.5% as Pai calls for public C-band auction https://seekingalpha.com/news/3520187-intelsatminus-17_5-pai-calls-for-public-c-band-auction?source=tweet\" data-url=\"https://seekingalpha.com/news/3520187-intelsatminus-17_5-pai-calls-for-public-c-band-auction\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>53&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520176\" data-ts=\"1574094535\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVIV\" target=\"_blank\">NVIV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520176-invivo-launches-equity-offering-shares-down-17\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">InVivo launches equity offering; shares down 17%</a></h4><ul><li>Thinly traded nano cap InVivo Therapeutics Holdings (<a href='https://seekingalpha.com/symbol/NVIV' title='InVivo Therapeutics Holdings Corp.'>NVIV</a> <font color=\"red\">-16.6%</font>) is down on almost a 5x surge in volume, albeit on turnover of only 115K shares, in reaction to its planned <a href=\"https://seekingalpha.com/pr/17702101-invivo-therapeutics-announces-proposed-public-offering-common-stock\" target=\"_blank\">public offering</a> of common stock. Price, volume and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520176\" data-linked=\"InVivo launches equity offering; shares down 17%\" data-tweet=\"$NVIV - InVivo launches equity offering; shares down 17% https://seekingalpha.com/news/3520176-invivo-launches-equity-offering-shares-down-17?source=tweet\" data-url=\"https://seekingalpha.com/news/3520176-invivo-launches-equity-offering-shares-down-17\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520173\" data-ts=\"1574094369\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GAPFF\" target=\"_blank\">GAPFF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520173-aimia-gains-6_3-after-settling-dissident-shareholders\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aimia gains 6.3% after settling with dissident shareholders</a></h4><ul><li>Aimia (<a href='https://seekingalpha.com/symbol/GAPFF' title='Aimia Inc.'>OTCPK:GAPFF</a>)<font color=\"green\"> climbs 6.3%</font> after the company <a href=\"https://seekingalpha.com/pr/17701839-aimia-announces-comprehensive-settlement-shareholder-litigation-related-matters\" target=\"_blank\">settles </a>with activist investors Mittleman Brothers and Charles Frischer, the leader of a group of requisitioning shareholders.</li><li>The parties agree to a governance process with the aim to reconstitute the board no later than Feb. 28, 2020, and in advance of the next annual meeting to be held no later than April 30, 2020.</li><li>The requisition of the special meeting has been withdrawn by Frischer and the requisitioning shareholders and the special meeting has been cancelled.</li><li>Aimia and Mittleman agree to take steps to have all legal proceedings between them and current and former directors dismissed with prejudice as soon as possible.</li><li>Along with the settlement, Aimia's board approves a C$125M substantial issuer bid.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520173\" data-linked=\"Aimia gains 6.3% after settling with dissident shareholders\" data-tweet=\"$GAPFF - Aimia gains 6.3% after settling with dissident shareholders https://seekingalpha.com/news/3520173-aimia-gains-6_3-after-settling-dissident-shareholders?source=tweet\" data-url=\"https://seekingalpha.com/news/3520173-aimia-gains-6_3-after-settling-dissident-shareholders\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520172\" data-ts=\"1574094346\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NOW\" target=\"_blank\">NOW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520172-servicenowplus-2_7-mcdermott-takes-reins\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ServiceNow +2.7% as McDermott takes reins</a></h4><ul><li>Bill McDermott <a href=\"https://seekingalpha.com/pr/17702119-servicenow-names-gina-mastantuono-chief-financial-officer\" target=\"_blank\">takes on</a> his ServiceNow (NYSE:<a href='https://seekingalpha.com/symbol/NOW' title='ServiceNow, Inc.'>NOW</a>) CEO duties earlier than expected.</li><li>Last month, the SAP CEO said he was stepping down but would remain with the company through the end of the year to help with the transition. He was then hired on at ServiceNow.</li><li>NOW also announces Gina Mastantuono as the new CFO, effective January 13. She joins from her CFO role at Ingram Micro.</li><li>ServiceNow shares are <font color=\"green\">up 2.7%</font> to $267.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520172\" data-linked=\"ServiceNow +2.7% as McDermott takes reins\" data-tweet=\"$NOW - ServiceNow +2.7% as McDermott takes reins https://seekingalpha.com/news/3520172-servicenowplus-2_7-mcdermott-takes-reins?source=tweet\" data-url=\"https://seekingalpha.com/news/3520172-servicenowplus-2_7-mcdermott-takes-reins\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:25 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520167\" data-ts=\"1574093857\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520167-skittish-trading-on-mall-names\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Skittish trading on mall names</a></h4><ul> <li>Select apparel store stocks are underperforming on the day amid pessimism that the U.S.-China trade battle will extend further than hoped and some strategic positioning ahead of a busy week of retail earnings reports.</li> <li>Notable decliners include Abercrombie &amp; Fitch (<a href='https://seekingalpha.com/symbol/ANF' title='Abercrombie & Fitch Co.'>ANF</a> <font color='red'>-7%</font>), American Eagle Outfitters (<a href='https://seekingalpha.com/symbol/AEO' title='American Eagle Outfitters, Inc.'>AEO</a> <font color='red'>-3.2%</font>), Gap (<a href='https://seekingalpha.com/symbol/GPS' title='The Gap, Inc.'>GPS</a> <font color='red'>-2.1%</font>), Express (<a href='https://seekingalpha.com/symbol/EXPR' title='Express, Inc.'>EXPR</a> <font color='red'>-3.9%</font>), RTW Retailwinds (<a href='https://seekingalpha.com/symbol/RTW' title='RTW Retailwinds, Inc.'>RTW</a> <font color='red'>-3.5%</font>), Francesca's (<a href='https://seekingalpha.com/symbol/FRAN' title='Francesca&#39;s Holdings Corporation'>FRAN</a> <font color='red'>-0.9%</font>) and Destination XL (<a href='https://seekingalpha.com/symbol/DXLG' title='Destination XL Group, Inc.'>DXLG</a> <font color='red'>-3.3%</font>).</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3520167\" data-linked=\"Skittish trading on mall names\" data-tweet=\"$ANF $AEO $GPS - Skittish trading on mall names https://seekingalpha.com/news/3520167-skittish-trading-on-mall-names?source=tweet\" data-url=\"https://seekingalpha.com/news/3520167-skittish-trading-on-mall-names\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520161\" data-ts=\"1574093466\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CPST\" target=\"_blank\">CPST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520161-capstone-turbine-wins-flare-gas-project-order-from-ecopetrol\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Capstone Turbine wins flare gas project order from Ecopetrol</a></h4><ul><li>Capstone Turbine (<a href='https://seekingalpha.com/symbol/CPST' title='Capstone Turbine Corporation'>CPST</a> <font color='green'>+18.7%</font>) surges on news it received an <a href=\"https://seekingalpha.com/pr/17702180-capstone-secures-significant-1-mw-flare-gas-project-ecopetrol-largest-national-oil-company\" target=\"_blank\">order for its first-ever flare gas project</a> from Ecopetrol (<a href='https://seekingalpha.com/symbol/EC' title='Ecopetrol S.A.'>EC</a> <font color='red'>-1.4%</font>), which is replacing one of its reciprocating engine generators in the Rio Ceibas field in Colombia; financial terms are not disclosed.</li><li>CPST says Supernova Energy Services, its exclusive distributor for Colombia and Venezuela, secured the order for the 1 MW project, which is expected to be commissioned by the end of the year.</li><li>CPST says its C1000 Signature Series will provide electrical power for site operations with associated gas from the oil extraction process that otherwise would have been flared into the atmosphere.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520161\" data-linked=\"Capstone Turbine wins flare gas project order from Ecopetrol\" data-tweet=\"$CPST $EC - Capstone Turbine wins flare gas project order from Ecopetrol https://seekingalpha.com/news/3520161-capstone-turbine-wins-flare-gas-project-order-from-ecopetrol?source=tweet\" data-url=\"https://seekingalpha.com/news/3520161-capstone-turbine-wins-flare-gas-project-order-from-ecopetrol\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520158\" data-ts=\"1574093148\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JMIA\" target=\"_blank\">JMIA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520158-jumia-pulls-e-commerce-business-in-cameroon\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jumia pulls e-commerce business in Cameroon</a></h4><ul><li>Jumia Technologies (NYSE:<a href='https://seekingalpha.com/symbol/JMIA' title='Jumia Technologies AG'>JMIA</a>) <a href=\"https://www.reuters.com/article/us-jumia-tech-cameroon/jumia-technologies-suspends-e-commerce-business-in-cameroon-idUSKBN1XS1YK?feedType=RSS&amp;feedName=technologyNews&amp;utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+reuters%2FtechnologyNews+%28Reuters+Technology+News%29\" target=\"_blank\">suspends</a> its e-commerce business in Cameroon, saying the portal isn't \"suitable to the current context\" in the country.</li><li>The company will continue supporting buyers and vendors through its Jumia Deals classified portal.</li><li>JMIA shares are <font color=\"red\">down 7.9%</font> to $5.06. Shares are down 78% YTD since the April IPO.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520158\" data-linked=\"Jumia pulls e-commerce business in Cameroon\" data-tweet=\"$JMIA - Jumia pulls e-commerce business in Cameroon https://seekingalpha.com/news/3520158-jumia-pulls-e-commerce-business-in-cameroon?source=tweet\" data-url=\"https://seekingalpha.com/news/3520158-jumia-pulls-e-commerce-business-in-cameroon\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520156\" data-ts=\"1574093051\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520156-healthcare-top-5-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers</a></h4><ul><li><b>Gainers: </b>Karuna Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/KRTX' title='Karuna Therapeutics, Inc.'>KRTX</a>) <font color=\"green\">+233%</font>. Matinas BioPharma Holdings (NYSEMKT:<a href='https://seekingalpha.com/symbol/MTNB' title='Matinas BioPharma Holdings, Inc.'>MTNB</a>) <font color=\"green\">+25%</font>. Dicerna Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/DRNA' title='Dicerna Pharmaceuticals, Inc.'>DRNA</a>) <font color=\"green\">+18%</font>. Xtant Medical Holdings (NYSEMKT:<a href='https://seekingalpha.com/symbol/XTNT' title='Xtant Medical Holdings, Inc.'>XTNT</a>) <font color=\"green\">+17%</font>. Artelo Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/ARTL' title='Artelo Biosciences, Inc.'>ARTL</a>) <font color=\"green\">+16%</font>.</li><li><b>Losers: </b>Anchiano Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ANCN' title='Anchiano Therapeutics Ltd'>ANCN</a>) <font color=\"red\">-21%</font>. SELLAS Life Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/SLS' title='SELLAS Life Sciences Group, Inc.'>SLS</a>) <font color=\"red\">-18%</font>. Cancer Genetics (NASDAQ:<a href='https://seekingalpha.com/symbol/CGIX' title='Cancer Genetics, Inc.'>CGIX</a>) <font color=\"red\">-12%</font>. Therapix Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/TRPX' title='Therapix Biosciences Ltd.'>TRPX</a>) <font color=\"red\">-12%</font>. Abiomed (NASDAQ:<a href='https://seekingalpha.com/symbol/ABMD' title='Abiomed, Inc.'>ABMD</a>) <font color=\"red\">-11%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520156\" data-linked=\"Healthcare - Top 5 Gainers / Losers\" data-tweet=\"$KRTX $MTNB $DRNA - Healthcare - Top 5 Gainers / Losers https://seekingalpha.com/news/3520156-healthcare-top-5-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3520156-healthcare-top-5-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:04 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520150\" data-ts=\"1574091593\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520150-procter-gamble-looks-to-get-well-in-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Procter &amp; Gamble looks to get well in healthcare</a></h4><ul> <li>Procter &amp; Gamble (<a href='https://seekingalpha.com/symbol/PG' title='The Procter & Gamble Company'>PG</a> <font color='green'>+1.4%</font>) is making a stronger push into DIY healthcare with more products aimed at consumers looking into wellness <a href=\"https://www.wsj.com/articles/p-g-pursues-the-do-it-yourself-health-care-business-11574084384\" target=\"_blank\">options</a>, observes <em>The Wall Street Journal's</em> Sharon Terlep.</li>  <li>P&amp;G is offering more vitamins, supplements, nonprescription sleep aids and all-natural menopause treatments to follow the path into healthcare/wellness categories by rivals like Clorox (<a href='https://seekingalpha.com/symbol/CLX' title='The Clorox Company'>CLX</a> <font color='green'>+1.2%</font>) and Unilever (<a href='https://seekingalpha.com/symbol/UN' title='The Unilever Group'>UN</a>, <a href='https://seekingalpha.com/symbol/UL' title='The Unilever Group'>UL</a>).</li> <li>The company is also using its venture arm to partner on new online healthcare brands.</li><li>Underpinning the strategy, the categories being looked at by P&amp;G tend to have higher margins than the rest of its consumer products business.</li><li>Shares of Procter &amp; Gamble are up 33% YTD.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3520150\" data-linked=\"Procter &amp; Gamble looks to get well in healthcare\" data-tweet=\"$PG $CLX $UN - Procter &amp; Gamble looks to get well in healthcare https://seekingalpha.com/news/3520150-procter-gamble-looks-to-get-well-in-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3520150-procter-gamble-looks-to-get-well-in-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520141\" data-ts=\"1574090862\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRIP\" target=\"_blank\">TRIP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520141-tripadvisorplus-2_5-former-bear-hits-sidelines\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TripAdvisor +2.5% as former bear hits sidelines</a></h4><ul><li>TripAdvisor (NASDAQ:<a href='https://seekingalpha.com/symbol/TRIP' title='TripAdvisor, Inc.'>TRIP</a>) is upgraded from Underperform to Market Perform at Cowen.</li><li>The target is dropped from $39 to $30.</li><li>The firm notes the pullback since the <a href=\"https://seekingalpha.com/news/3515871-tripadvisor-reports-downside-q3-trip-com-partnership\" target=\"_blank\">Q3 results</a>. TRIP shares are <font color=\"red\">down 20%</font> this month.</li><li>TRIP shares are <font color=\"green\">up 2.5%</font> to $31.91.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520141\" data-linked=\"TripAdvisor +2.5% as former bear hits sidelines\" data-tweet=\"$TRIP - TripAdvisor +2.5% as former bear hits sidelines https://seekingalpha.com/news/3520141-tripadvisorplus-2_5-former-bear-hits-sidelines?source=tweet\" data-url=\"https://seekingalpha.com/news/3520141-tripadvisorplus-2_5-former-bear-hits-sidelines\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520138\" data-ts=\"1574090347\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WDAY\" target=\"_blank\">WDAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520138-workdayminus-1_3-on-downgrade-for-hcm-concerns\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Workday -1.3% on downgrade for HCM concerns</a></h4><ul><li>Morgan Stanley downgrades Workday (NASDAQ:<a href='https://seekingalpha.com/symbol/WDAY' title='Workday, Inc.'>WDAY</a>) from Overweight to Equal-Weight and cuts the target from $219 to $180.</li><li>The firm cites \"slowing momentum\" in the HCM business and the more difficult spending environment.</li><li>Morgan notes that recent management comments, including on HCM growth, \"have caused concern over the growth trajectory.\"</li><li>WDAY share are <font color=\"red\">down 1.3%</font> to $163.90.</li><li>The company has a Neutral <a href=\"https://seekingalpha.com/symbol/WDAY/ratings/quant-ratings\" target=\"_blank\">Quant rating</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520138\" data-linked=\"Workday -1.3% on downgrade for HCM concerns\" data-tweet=\"$WDAY - Workday -1.3% on downgrade for HCM concerns https://seekingalpha.com/news/3520138-workdayminus-1_3-on-downgrade-for-hcm-concerns?source=tweet\" data-url=\"https://seekingalpha.com/news/3520138-workdayminus-1_3-on-downgrade-for-hcm-concerns\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520136\" data-ts=\"1574090195\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABMD\" target=\"_blank\">ABMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520136-abiomed-down-9-on-study-questioning-value-of-impella-heart-pump\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Abiomed down 9% on study questioning value of Impella heart pump</a></h4><ul><li>Abiomed (<a href='https://seekingalpha.com/symbol/ABMD' title='Abiomed, Inc.'>ABMD</a> <font color=\"red\">-9.4%</font>) slumps on increased volume in early trade in apparent response to a <a href=\"https://consumer.healthday.com/general-health-information-16/misc-surgery-news-650/expensive-device-used-in-heart-surgeries-might-pose-dangers-study-752231.html\" target=\"_blank\">pair of studies</a> that showed its Impella heart pump is associated with higher mortality risk, bleeding and stroke in patients undergoing angioplasty to re-open clogged arteries. The data were presented at the American Heart Association Scientific Sessions in Philadelphia.</li><li>\"The associated clinical outcomes did not show any substantial improvement, while costs of hospitalization rose,\" said Dr. Amit Amin, lead researcher for one of the two teams and an assistant professor at the Washington University School of Medicine in St. Louis.</li><li>~45% of patients died during Impella-involved procedures compared to 34% of those whose blood flow was supported by an intra-aortic balloon. ~31% of patients with cardiogenic shock who were treated with Impella experienced major bleeding versus 16% who were treated with the balloon.</li><li>The use of the device added ~$15K to the average hospital tab according to the researchers.</li><li>Unsurprisingly, the company countered that repeated studies proved Impella's safety and efficacy. Data from a recent trial, for example, showed a 29% reduction in serious heart complications compared to the balloon.</li><li>Impella is used in ~1/3 of angioplasty procedures to provide blood flow support.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520136\" data-linked=\"Abiomed down 9% on study questioning value of Impella heart pump\" data-tweet=\"$ABMD - Abiomed down 9% on study questioning value of Impella heart pump https://seekingalpha.com/news/3520136-abiomed-down-9-on-study-questioning-value-of-impella-heart-pump?source=tweet\" data-url=\"https://seekingalpha.com/news/3520136-abiomed-down-9-on-study-questioning-value-of-impella-heart-pump\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>68&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520134\" data-ts=\"1574089442\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DHI\" target=\"_blank\">DHI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520134-bofa-sees-solid-demand-backdrop-for-d-r-horton-in-2020\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BofA sees &#39;solid demand backdrop&#39; for D.R. Horton in 2020</a></h4><ul><li>D.R. Horton (NYSE:<a href='https://seekingalpha.com/symbol/DHI' title='D.R. Horton, Inc.'>DHI</a>)<font color=\"green\"> gains 1.0%</font> after Bank of America analyst John Lovallo writes that the homebuilder and its majority-owned Forestar Group (NYSE:<a href='https://seekingalpha.com/symbol/FOR' title='Forestar Group Inc.'>FOR</a>) present \"a united force leading the homebuilding industry.\"</li><li>Lovallo sees strong demand going into 2020, as DHI is experiencing \"broad-based strength\" across its footprint and buyers appear to be ignoring \"geopolitical noise.\"</li><li>Meanwhile, Raymond James notes that DHI is \"firing on all cylinders\" and maintains a market perform, \"solely on valuation.\"</li><li>D.R. Horton<a href=\"https://seekingalpha.com/symbol/DHI/momentum/performance\" target=\"_blank\"> has risen 21% </a>in the past six months compared with the consumer discretionary sector median performance of -0.3% during the same period.</li><li>Quant rating <a href=\"https://seekingalpha.com/symbol/DHI/ratings/quant-ratings\" target=\"_blank\">Very Bullish</a>; Sell-Side average rating is <a href=\"https://seekingalpha.com/symbol/DHI/ratings/sell-side-ratings\" target=\"_blank\">Bullish</a> (8 Very Bullish, 2 Bullilsh, 10 Neutral).</li></ul><div class=\"tiny-share-widget\" data-id=\"3520134\" data-linked=\"BofA sees &#39;solid demand backdrop&#39; for D.R. Horton in 2020\" data-tweet=\"$DHI $DHI $FOR - BofA sees &#39;solid demand backdrop&#39; for D.R. Horton in 2020 https://seekingalpha.com/news/3520134-bofa-sees-solid-demand-backdrop-for-d-r-horton-in-2020?source=tweet\" data-url=\"https://seekingalpha.com/news/3520134-bofa-sees-solid-demand-backdrop-for-d-r-horton-in-2020\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520130\" data-ts=\"1574088785\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MED\" target=\"_blank\">MED</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520130-medifast-up-6-key-investors-make-moves\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Medifast up 6% as key investors make moves</a></h4><ul><li>Medifast (<a href='https://seekingalpha.com/symbol/MED' title='Medifast, Inc.'>MED</a> <font color=\"green\">+6.1%</font>) is up on average volume in early trade in apparent reaction to two events: activist investor Engaged Capital's <a href=\"https://www.sec.gov/Archives/edgar/data/910329/000119380519001450/sc13d09455006_11152019.htm\" target=\"_blank\">9.99% stake</a> and the \"<a href=\"https://twitter.com/GothamResearch/status/1196431185917943809\" target=\"_blank\">moving on</a>\" by short-seller Gotham City Research due to changing \"facts.\"</li><li>Shares plummeted last week after its <a href=\"https://seekingalpha.com/news/3517104-medifast-29-percent-premarket-q3-miss-guidance-cut\" target=\"_blank\">Q3 miss</a> and guidance cut.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520130\" data-linked=\"Medifast up 6% as key investors make moves\" data-tweet=\"$MED - Medifast up 6% as key investors make moves https://seekingalpha.com/news/3520130-medifast-up-6-key-investors-make-moves?source=tweet\" data-url=\"https://seekingalpha.com/news/3520130-medifast-up-6-key-investors-make-moves\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:53 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520118\" data-ts=\"1574088301\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDCO\" target=\"_blank\">MDCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520118-medicines-companys-inclisiran-shows-positive-effect-in-hefh-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">The Medicines Company&#39;s inclisiran shows positive effect in HeFH study</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/17702275-medicines-company-announces-orionminus-9-study-inclisiran-hefh-patients-showed-durable-potent\" target=\"_blank\">Results </a>from a Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03397121\" target=\"_blank\">ORION-9</a>, evaluating the effect of The Medicines Company's (<a href='https://seekingalpha.com/symbol/MDCO' title='The Medicines Company'>MDCO</a> <font color=\"green\">+2.3%</font>) inclisiran on reducing \"bad\" cholesterol (LDL-C) in patients with familial hypercholesterolemia &#40;FH&#41;, an inherited condition characterized by abnormally high levels of cholesterol in the blood, showed a treatment benefit. The data were presented at the American Heart Association Scientific Sessions in Philadelphia.</li><li>The study met the primary endpoints of percent change in LDL-C from baseline to day 510 (50% reduction) versus placebo and time-averaged percent change (45% reduction) in LDL-C after day 90 up to day 510 versus control. Both values were statistically significant.</li><li>No new safety signals were observed.</li><li>The results will be submitted for presentation in a peer-reviewed medical journal. The company expects to file a U.S. marketing application this quarter and one in Europe next quarter.</li><li>The company will host a conference call today at 12 noon ET to discuss the results from ORION-9 and <a href=\"https://seekingalpha.com/news/3520048-medicines-company-2-percent-premarket-positive-inclisiran-data\" target=\"_blank\">ORION-10</a>.</li><li>Related ticker: Alnylam Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ALNY' title='Alnylam Pharmaceuticals, Inc.'>ALNY</a> <font color=\"red\">-0.7%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3520118\" data-linked=\"The Medicines Company&#39;s inclisiran shows positive effect in HeFH study\" data-tweet=\"$MDCO $ALNY - The Medicines Company&#39;s inclisiran shows positive effect in HeFH study https://seekingalpha.com/news/3520118-medicines-companys-inclisiran-shows-positive-effect-in-hefh-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3520118-medicines-companys-inclisiran-shows-positive-effect-in-hefh-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:45 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520119\" data-ts=\"1574088264\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JEF\" target=\"_blank\">JEF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520119-jefferiesplus-2_5-after-kbw-expects-stock-buyback\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jefferies +2.5% after KBW expects stock buyback</a></h4><ul><li>Jefferies Financial Group (NYSE:<a href='https://seekingalpha.com/symbol/JEF' title='Jefferies Financial Group Inc.'>JEF</a>) <font color=\"green\">rises 2.5%</font> after KBW analyst Michael Brown writes that the company may buy back stock, using a gain and freed-up capital from selling its National Beef stake for $970M.</li><li>Yesterday, Jefferies<a href=\"https://seekingalpha.com/pr/17701629-jefferies-agrees-sell-remaining-31-percent-interest-national-beef-marfrig\" target=\"_blank\"> agreed to sell</a> its remaining 31% interest in National Beef to Marfrig Global Foods and expects to recognize a pretax gain of ~$210M; sees deal closing by the end of the month.</li><li>The company may reduce its share count by ~20%, if completed in 2020, and bring Jefferies close to its target of 250M shares outstanding, Brown said.</li><li>The sale, though, could be a near-term challenge as National Beef was the strongest cash-flow business within the Merchant Bank, he wrote.</li><li>Rates JEF market perform with a $22 price target.</li><li>Sell-Side average rating is <a href=\"https://seekingalpha.com/symbol/JEF/ratings/sell-side-ratings\" target=\"_blank\">Bullish </a>(1 Very Bullish, 1 Neutral).</li></ul><div class=\"tiny-share-widget\" data-id=\"3520119\" data-linked=\"Jefferies +2.5% after KBW expects stock buyback\" data-tweet=\"$JEF - Jefferies +2.5% after KBW expects stock buyback https://seekingalpha.com/news/3520119-jefferiesplus-2_5-after-kbw-expects-stock-buyback?source=tweet\" data-url=\"https://seekingalpha.com/news/3520119-jefferiesplus-2_5-after-kbw-expects-stock-buyback\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:44 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520109\" data-ts=\"1574086965\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VSAT\" target=\"_blank\">VSAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520109-viasatplus-5-jpmorgan-raises-to-overweight\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Viasat +5% as JPMorgan raises to Overweight</a></h4><ul>   <li>Viasat (NASDAQ:<a href='https://seekingalpha.com/symbol/VSAT' title='Viasat, Inc.'>VSAT</a>) is <font color=\"green\">up 5.1%</font> premarket after an upgrade to Overweight at JPMorgan, from Neutral.</li>    <li>The firm raised its price target to $90 from $84, implying 25% upside.</li>    <li>Overall, the <a href=\"https://seekingalpha.com/symbol/VSAT/ratings/sell-side-ratings\" target=\"_blank\">sell side is Bullish</a> on Viasat, and the stock has a <a href=\"https://seekingalpha.com/symbol/VSAT/ratings/quant-ratings\" target=\"_blank\">Quant Rating of Neutral</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3520109\" data-linked=\"Viasat +5% as JPMorgan raises to Overweight\" data-tweet=\"$VSAT - Viasat +5% as JPMorgan raises to Overweight https://seekingalpha.com/news/3520109-viasatplus-5-jpmorgan-raises-to-overweight?source=tweet\" data-url=\"https://seekingalpha.com/news/3520109-viasatplus-5-jpmorgan-raises-to-overweight\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:22 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520106\" data-ts=\"1574086701\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520106-cpst-yndx-among-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CPST, YNDX among premarket gainers</a></h4><ul><li>Karuna Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/KRTX' title='Karuna Therapeutics, Inc.'>KRTX</a>) <font color=\"green\">+80%</font> on positive KarXT <a href=\"https://seekingalpha.com/news/3520035-karuna-86-percent-premarket-positive-karxt-data\" target=\"_blank\">data</a>.</li><li>Eros International Plc (NYSE:<a href='https://seekingalpha.com/symbol/EROS' title='Eros International Plc'>EROS</a>) <font color=\"green\">+21%</font> on <a href=\"https://seekingalpha.com/pr/17701966-eros-now-announces-collaboration-youtube-music\" target=\"_blank\">collaboration</a> with YouTube Music.</li><li>Capstone Turbine (NASDAQ:<a href='https://seekingalpha.com/symbol/CPST' title='Capstone Turbine Corporation'>CPST</a>) <font color=\"green\">+21%</font> on <a href=\"https://seekingalpha.com/pr/17702180-capstone-secures-significant-1-mw-flare-gas-project-ecopetrol-largest-national-oil-company\" target=\"_blank\">securing</a> Significant 1 MW Flare Gas Project with Ecopetrol.</li><li>Caladrius Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/CLBS' title='Caladrius Biosciences, Inc.'>CLBS</a>) <font color=\"green\">+11%</font> on <a href=\"https://seekingalpha.com/pr/17701556-caladrius-biosciences-reports-positive-results-clbs16-escape-cmd-trial-american-heart\" target=\"_blank\">positive results</a> for CLBS16 from the ESCaPE-CMD Trial.</li><li>Matinas BioPharma Holdings (NYSEMKT:<a href='https://seekingalpha.com/symbol/MTNB' title='Matinas BioPharma Holdings, Inc.'>MTNB</a>) <font color=\"green\">+9%</font>.</li><li>Xunlei (NASDAQ:<a href='https://seekingalpha.com/symbol/XNET' title='Xunlei Limited'>XNET</a>) <font color=\"green\">+7%</font> on <a href=\"https://seekingalpha.com/pr/17702069-xunlei-collaborates-china-tower-corporation-edge-computing-project\" target=\"_blank\">collaboration</a> with China Tower on edge computing project.</li><li>resTORbio (NASDAQ:<a href='https://seekingalpha.com/symbol/TORC' title='resTORbio, Inc.'>TORC</a>) <font color=\"green\">+6%</font>.</li><li>Yandex N.V. (NASDAQ:<a href='https://seekingalpha.com/symbol/YNDX' title='Yandex N.V.'>YNDX</a>) <font color=\"green\">+6%</font> on $300M <a href=\"https://seekingalpha.com/news/3520004-yandex-authorizes-share-repurchase-program-shares-6-percent-premarket\" target=\"_blank\">share repurchase program</a>.</li><li>Puxin (NYSE:<a href='https://seekingalpha.com/symbol/NEW' title='Puxin Limited'>NEW</a>) <font color=\"green\">+6%</font> after <a href=\"https://seekingalpha.com/news/3520001-puxin-reports-q3-results\" target=\"_blank\">Q3 results</a>.</li><li>Bloom Energy (NYSE:<a href='https://seekingalpha.com/symbol/BE' title='Bloom Energy Corporation'>BE</a>) <font color=\"green\">+6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520106\" data-linked=\"CPST, YNDX among premarket gainers\" data-tweet=\"$KRTX $EROS $CPST - CPST, YNDX among premarket gainers https://seekingalpha.com/news/3520106-cpst-yndx-among-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3520106-cpst-yndx-among-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520105\" data-ts=\"1574086586\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLBS\" target=\"_blank\">CLBS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520105-caladrius-bio-up-14-premarket-on-positive-clbs16-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Caladrius Bio up 14% premarket on positive CLBS16 data</a></h4><ul><li>Ultra-thinly traded nano cap Caladrius Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/CLBS' title='Caladrius Biosciences, Inc.'>CLBS</a>) is up <font color=\"green\">14%</font> premarket on increased volume, albeit on turnover of only 25K shares, in reaction to <a href=\"https://seekingalpha.com/pr/17701556-caladrius-biosciences-reports-positive-results-clbs16-escape-cmd-trial-american-heart\" target=\"_blank\">results </a>from a proof-of-concept study, ESCaPE-CMD, evaluating autologous CD34+ cell therapy CLBS16 in patients with coronary microvascular dysfunction &#40;CMD&#41;. The data were presented at the American Heart Association Scientific Sessions in Philadelphia.</li><li>Results from 17 participants who completed the six-month follow-up period after a single intracoronary injection of CLBS16 showed a statistically significant increase in coronary flow reserve as well as statistically valid improvements in chest pain frequency, Canadian Cardiovascular Society angina classification and Seattle Angina Questionnaire scores.</li><li>Follow-up data from the remaining three patients should be available by year-end.</li><li>CMD, primarily affecting women, is a type of non-obstructive coronary artery disease that causes decreased blood flow to heart muscle.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520105\" data-linked=\"Caladrius Bio up 14% premarket on positive CLBS16 data\" data-tweet=\"$CLBS - Caladrius Bio up 14% premarket on positive CLBS16 data https://seekingalpha.com/news/3520105-caladrius-bio-up-14-premarket-on-positive-clbs16-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3520105-caladrius-bio-up-14-premarket-on-positive-clbs16-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520102\" data-ts=\"1574086494\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ENPH\" target=\"_blank\">ENPH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520102-enphase-to-supply-sunrun-microinverters\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Enphase to supply Sunrun with microinverters</a></h4><ul><li>Enphase Energy (NASDAQ:<a href='https://seekingalpha.com/symbol/ENPH' title='Enphase Energy, Inc.'>ENPH</a>) <font color=\"green\">+4.5%</font> pre-market on news it <a href=\"https://seekingalpha.com/pr/17702015-enphase-energy-announces-strategic-supply-agreement-sunrun\" target=\"_blank\">signed a supply agreement</a> with Sunrun (NASDAQ:<a href='https://seekingalpha.com/symbol/RUN' title='Sunrun Inc.'>RUN</a>) to provide its seventh-generation Enphase IQ microinverters for  use in RUN's residential solar business; financial terms are not disclosed.</li><li>\"Enphase microinverters are reliable, simple to install and feature sophisticated remote monitoring capabilities,\" RUN CEO Lynn Jurich says in praising the deal.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520102\" data-linked=\"Enphase to supply Sunrun with microinverters\" data-tweet=\"$ENPH $RUN - Enphase to supply Sunrun with microinverters https://seekingalpha.com/news/3520102-enphase-to-supply-sunrun-microinverters?source=tweet\" data-url=\"https://seekingalpha.com/news/3520102-enphase-to-supply-sunrun-microinverters\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>128&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520101\" data-ts=\"1574086421\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EROS\" target=\"_blank\">EROS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520101-erosplus-16-on-youtube-partnership\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eros +16% on YouTube partnership</a></h4><ul><li>Under <a href=\"https://seekingalpha.com/pr/17701966-eros-now-announces-collaboration-youtube-music\" target=\"_blank\">the collab</a> with YouTube in India, Eros Now (NYSE:<a href='https://seekingalpha.com/symbol/EROS' title='Eros International Plc'>EROS</a>) will offer a special subscription package priced at 99 Indian rupees for 90 days.</li><li>The package will be available to all new subscribers of YouTube Music Premium and Google (NASDAQ:<a href='https://seekingalpha.com/symbol/GOOG' title='Alphabet Inc.'>GOOG</a>) (NASDAQ:<a href='https://seekingalpha.com/symbol/GOOGL' title='Alphabet Inc.'>GOOGL</a>) Play Music in the region.</li><li>Eros shares are <font color=\"green\">up 16%</font> pre-market to $2.47.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520101\" data-linked=\"Eros +16% on YouTube partnership\" data-tweet=\"$EROS $EROS $GOOG - Eros +16% on YouTube partnership https://seekingalpha.com/news/3520101-erosplus-16-on-youtube-partnership?source=tweet\" data-url=\"https://seekingalpha.com/news/3520101-erosplus-16-on-youtube-partnership\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520099\" data-ts=\"1574086086\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520099-qd-hexo-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">QD, HEXO among premarket losers</a></h4><ul><li>SELLAS Life Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/SLS' title='SELLAS Life Sciences Group, Inc.'>SLS</a>) <font color=\"red\">-21%</font>.</li><li>Senmiao Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/AIHS' title='Senmiao Technology Limited'>AIHS</a>) <font color=\"red\">-8%</font>.</li><li>Qudian (NYSE:<a href='https://seekingalpha.com/symbol/QD' title='Qudian Inc.'>QD</a>) <font color=\"red\">-8%</font> on <a href=\"https://seekingalpha.com/news/3520006-qudian-eps-misses-0_04-beats-revenue\" target=\"_blank\">Q3 earnings</a>.</li><li>Astrotech (NASDAQ:<a href='https://seekingalpha.com/symbol/ASTC' title='Astrotech Corporation'>ASTC</a>) <font color=\"red\">-6%</font>.</li><li>HEXO (NYSE:<a href='https://seekingalpha.com/symbol/HEXO' title='HEXO Corp.'>HEXO</a>) <font color=\"red\">-5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3520099\" data-linked=\"QD, HEXO among premarket losers\" data-tweet=\"$SLS $AIHS $QD - QD, HEXO among premarket losers https://seekingalpha.com/news/3520099-qd-hexo-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3520099-qd-hexo-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520098\" data-ts=\"1574085945\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LL\" target=\"_blank\">LL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520098-lumber-liquidatorsplus-4-after-ustr-determination\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lumber Liquidators +4% after USTR determination</a></h4><ul> <li>Lumber Liquidators (NYSE:<a href='https://seekingalpha.com/symbol/LL' title='Lumber Liquidators Holdings, Inc.'>LL</a>) tracks higher after stating the company believes based off a USTR ruling that flooring products are now excluded from the 25% tariff on Chinese goods. The exclusion includes specific vinyl and engineered products the company has sold and continues to sell.</li> <li>Lumber Liquidators says it's evaluating the details of the USTR exclusion and determining the potential current and future impact of it.</li>    <li><a href=\"https://seekingalpha.com/filing/4703070\" target=\"_blank\">SEC Form 8-K</a></li> <li>Shares of LL are <font color=\"green\">up 3.58%</font> premarket to $9.25.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3520098\" data-linked=\"Lumber Liquidators +4% after USTR determination\" data-tweet=\"$LL - Lumber Liquidators +4% after USTR determination https://seekingalpha.com/news/3520098-lumber-liquidatorsplus-4-after-ustr-determination?source=tweet\" data-url=\"https://seekingalpha.com/news/3520098-lumber-liquidatorsplus-4-after-ustr-determination\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520094\" data-ts=\"1574085608\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/COTY\" target=\"_blank\">COTY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520094-cotyplus-5-after-striking-kylie-jenner-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Coty +5% after striking Kylie Jenner deal</a></h4><ul> <li>Coty (NYSE:<a href='https://seekingalpha.com/symbol/COTY' title='Coty Inc.'>COTY</a>) announces a strategic partnership with Kylie Jenner.</li><li>Coty and Kylie plan to focus on global expansion and entry into new beauty categories. Jenner brands, Kylie Cosmetics and Kylie Skin, are already two of the fastest-growing and most-engaged beauty brands on social media.</li> <li>Coty says it will have overall responsibility for the portfolio's development and will leverage its global knowledge and capabilities in R&amp;D, manufacturing, distribution, commercial and go-to-market expertise. Coty will also act as a licensee for skincare, fragrances and nail products.</li> <li>All beauty categories within the new partnership will continue to be sold through leading luxury beauty retailers, as well as owned digital channels.</li><li>Under the terms of the deal, Coty will acquire a 51% ownership in the partnership for $600M. Coty expects the transaction will be accretive on a sales basis to its core fragrance, cosmetics and skin care portfolio by more than 1% over the next three years. The transaction is expected to be neutral to Coty\u2019s earnings per share in year one, and accretive thereafter.</li>  <li>The transaction is expected to close in Q3 of FY20.</li><li>COTY  <font color=\"green\">+4.95%</font> premarket to  $12.50.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17702238-coty-kylie-jenner-announce-strategic-partnership-expand-beauty-brands-globally\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3520094\" data-linked=\"Coty +5% after striking Kylie Jenner deal\" data-tweet=\"$COTY - Coty +5% after striking Kylie Jenner deal https://seekingalpha.com/news/3520094-cotyplus-5-after-striking-kylie-jenner-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3520094-cotyplus-5-after-striking-kylie-jenner-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520090\" data-ts=\"1574085039\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LX\" target=\"_blank\">LX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520090-lexinfintechplus-3_3-after-loan-origination-view-improves\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">LexinFintech +3.3% after loan origination view improves</a></h4><ul><li>LexinFintech Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/LX' title='LexinFintech Holdings Ltd.'>LX</a>) <font color=\"green\">climbs 3.3%</font> in premarket trading after Chinese online consumer finance platform boosts its <a href=\"https://seekingalpha.com/pr/17701720-lexinfintech-holdings-ltd-reports-third-quarter-2019-unaudited-financial-results\" target=\"_blank\">2019 loan origination guidance</a> range to RMB 115B-RMB 125B (~$16B-$18B) vs. its prior forecast of RMB 115B.</li><li>Q3 total loan originations of RMB 37.0B increased 170% vs. RMB13.7B in Q3 2018.</li><li>Q3 adjusted net income of RMB 714M, or RMB 3.86 (54 cents) per ADS, increased from RMB 466M in the year-ago quarter.</li><li>Q3 operating revenue of RMB 3.19B ($446.0M) rose from RMB 1.85B in the year-ago quarter, due to the increase in online direct sales revenue and financial services income for the quarter, driven by continuing increases in the number of active users on our platform.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3520000-lexinfintech-eps-line-beats-revenue\" target=\"_blank\">LexinFintech EPS in-line, beats on revenue</a> (Nov. 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3520090\" data-linked=\"LexinFintech +3.3% after loan origination view improves\" data-tweet=\"$LX - LexinFintech +3.3% after loan origination view improves https://seekingalpha.com/news/3520090-lexinfintechplus-3_3-after-loan-origination-view-improves?source=tweet\" data-url=\"https://seekingalpha.com/news/3520090-lexinfintechplus-3_3-after-loan-origination-view-improves\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:50 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520089\" data-ts=\"1574084937\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACST\" target=\"_blank\">ACST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520089-piper-likes-dexcom-in-premarket-analyst-action\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Piper likes DexCom in premarket analyst action</a></h4><ul><li>Acasti Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/ACST' title='Acasti Pharma Inc.'>ACST</a>) resumed with Buy rating and $8 (292% upside) price target at B. Riley FBR. Shares up <font color=\"green\">5% </font>premarket.</li><li>Champions Oncology (NASDAQ:<a href='https://seekingalpha.com/symbol/CSBR' title='Champions Oncology, Inc.'>CSBR</a>) initiated with Speculative Buy rating and $11 (104% upside) at Benchmark.</li><li>DexCom (NASDAQ:<a href='https://seekingalpha.com/symbol/DXCM' title='DexCom, Inc.'>DXCM</a>) initiated with Overweight rating and $230 (10% upside) price target at Piper Jaffray.</li><li>Infinity Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/INFI' title='Infinity Pharmaceuticals, Inc.'>INFI</a>) resumed with Buy rating and $3.50 (259% upside) price target at B. Riley FBR.</li><li>QIAGEN (NYSE:<a href='https://seekingalpha.com/symbol/QGEN' title='QIAGEN N.V.'>QGEN</a>) upgraded to Buy with a $48 (18% upside) price target at Commerzbank. Shares up <font color=\"green\">4%</font> premarket.</li><li>Amarin (NASDAQ:<a href='https://seekingalpha.com/symbol/AMRN' title='Amarin Corporation plc'>AMRN</a>) downgraded to Neutral with a $27 (13% upside) price target at Citigroup citing valuation as sales acceleration for Vascepa on expanded label already priced in. Shares up <font color=\"green\">2%</font> premarket.</li><li>Anchiano Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ANCN' title='Anchiano Therapeutics Ltd'>ANCN</a>) downgraded to Neutral at Ladenburg Thalmann.</li><li>Wright Medical Group (NASDAQ:<a href='https://seekingalpha.com/symbol/WMGI' title='Wright Medical Group N.V.'>WMGI</a>) downgraded to Market Perform with a $30.75 (4% upside) price target at SVB Leerink.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520089\" data-linked=\"Piper likes DexCom in premarket analyst action\" data-tweet=\"$ACST $CSBR $DXCM - Piper likes DexCom in premarket analyst action https://seekingalpha.com/news/3520089-piper-likes-dexcom-in-premarket-analyst-action?source=tweet\" data-url=\"https://seekingalpha.com/news/3520089-piper-likes-dexcom-in-premarket-analyst-action\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520088\" data-ts=\"1574084757\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TMUS\" target=\"_blank\">TMUS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520088-legere-stepping-down-t-mobile-ceo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Legere stepping down as T-Mobile CEO</a></h4><ul><li>Mike Sievert will succeed John Legere as T-Mobile (NASDAQ:<a href='https://seekingalpha.com/symbol/TMUS' title='T-Mobile US, Inc.'>TMUS</a>) CEO, effective May 1, 2020.</li><li>Sievert currently serves as T-Mobile's President and COO. He formerly served as the CMO.</li><li>T-Mobile <a href=\"https://seekingalpha.com/news/3519992-t-mobile-sets-business-update-call-monday-morning\" target=\"_blank\">will host</a> a business update call at 9 AM with a webcast <a href=\"https://investor.t-mobile.com/investors/default.aspx\" target=\"_blank\">here</a>.</li><li>The call will likely discuss progress with the Sprint merger.</li><li>TMUS shares are <font color=\"red\">down 1.7%</font> pre-market to $76.71.</li><li>Related: Last week, <a href=\"https://seekingalpha.com/news/3517637-wework-hiring-talks-t-mobile-chief-legere-wsj\" target=\"_blank\">reports surfaced</a> that Legere is on the shortlist of potential WeWork CEOs.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520088\" data-linked=\"Legere stepping down as T-Mobile CEO\" data-tweet=\"$TMUS - Legere stepping down as T-Mobile CEO https://seekingalpha.com/news/3520088-legere-stepping-down-t-mobile-ceo?source=tweet\" data-url=\"https://seekingalpha.com/news/3520088-legere-stepping-down-t-mobile-ceo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520085\" data-ts=\"1574084156\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FIZZ\" target=\"_blank\">FIZZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520085-tough-road-seen-for-lacroix\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tough road seen for LaCroix</a></h4><ul> <li>Guggenheim is the latest firm to warn on risk for National Beverage (NASDAQ:<a href='https://seekingalpha.com/symbol/FIZZ' title='National Beverage Corp.'>FIZZ</a>) with the LaCroix business.</li> <li>\"LaCroix will not stabilize until at least next year given the increased competition and the lack of meaningful innovation to generate buzz,\" warns analyst Laurent Grandet.</li><li>Coca-Cola (NYSE:<a href='https://seekingalpha.com/symbol/KO' title='The Coca-Cola Company'>KO</a>), PepsiCo (NASDAQ:<a href='https://seekingalpha.com/symbol/PEP' title='PepsiCo, Inc.'>PEP</a>) and Nestle (<a href='https://seekingalpha.com/symbol/NSRGY' title='Nestlé S.A.'>OTCPK:NSRGY</a>) are all competing with LaCroix.</li> <li>Guggenheim assigns a price target of $31 to FIZZ vs. the sell-side average PT of $42.50. The PT is below the 52-week low on FIZZ of $38.28</li> <li>Shares of National Beverage are down 40% YTD.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3520085\" data-linked=\"Tough road seen for LaCroix\" data-tweet=\"$FIZZ $FIZZ $KO - Tough road seen for LaCroix https://seekingalpha.com/news/3520085-tough-road-seen-for-lacroix?source=tweet\" data-url=\"https://seekingalpha.com/news/3520085-tough-road-seen-for-lacroix\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520081\" data-ts=\"1574083823\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VRTX\" target=\"_blank\">VRTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520081-vertex-teams-up-molecular-templates-in-hsct-conditioning-regimens\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vertex teams up with Molecular Templates in HSCT conditioning regimens</a></h4><ul><li>Vertex Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/VRTX' title='Vertex Pharmaceuticals Incorporated'>VRTX</a>) will <a href=\"https://seekingalpha.com/pr/17701845-vertex-molecular-templates-establish-collaboration-discover-develop-novel-targeted\" target=\"_blank\">collaborate </a>with Molecular Templates (NASDAQ:<a href='https://seekingalpha.com/symbol/MTEM' title='Molecular Templates, Inc.'>MTEM</a>) to discover and develop novel targeted conditioning regimens aimed at enhancing the process of hematopoietic stem cell transplantation &#40;HSCT&#41;, including transplants conducted as part of treatment with gene therapy candidate CTX001, in <a href=\"https://seekingalpha.com/news/3450962-crispr-vertexs-ctx001-fast-trackd-beta-thalassemia\" target=\"_blank\">Phase 1/2 development</a> with CRISPR Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CRSP' title='CRISPR Therapeutics AG'>CRSP</a>) for transfusion-dependent beta thalassemia and sickle cell disease.</li><li>The parties will focus their efforts on discovering a new conditioning regimen leveraging MTEM's <a href=\"https://mtem.com/etb-platform/pipeline/\" target=\"_blank\">engineered toxin body platform</a>, designed to boost the successful engraftment of new cells by selectively targeting and removing specific cells that can interfere with the process.</li><li>Under the terms of the agreement, VRTX will pay MTEM $38M upfront, including an equity investment, up to $522M in milestones and tiered royalties on net sales on up to two targets. VRTX will have the option to exclusively license the molecules against the designated targets for any indication.</li><li>MTEM is up <font color=\"green\">13%</font> premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520081\" data-linked=\"Vertex teams up with Molecular Templates in HSCT conditioning regimens\" data-tweet=\"$VRTX $MTEM $CRSP - Vertex teams up with Molecular Templates in HSCT conditioning regimens https://seekingalpha.com/news/3520081-vertex-teams-up-molecular-templates-in-hsct-conditioning-regimens?source=tweet\" data-url=\"https://seekingalpha.com/news/3520081-vertex-teams-up-molecular-templates-in-hsct-conditioning-regimens\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:30 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520048\" data-ts=\"1574081124\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDCO\" target=\"_blank\">MDCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520048-medicines-company-up-2-premarket-on-positive-inclisiran-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">The Medicines Company up 2% premarket on positive inclisiran data</a></h4><ul><li>The Medicines Company (NASDAQ:<a href='https://seekingalpha.com/symbol/MDCO' title='The Medicines Company'>MDCO</a>) is up <font color=\"green\">2%</font> premarket on light volume in reaction to <a href=\"https://seekingalpha.com/pr/17701543-medicines-company-announces-orionminus-10-study-inclisiran-ascvd-patients-showed-durable\" target=\"_blank\">positive results</a> from a Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03399370?titles=orion-10&amp;lead=the+medicines+company&amp;phase=2&amp;draw=2&amp;rank=1\" target=\"_blank\">ORION-10</a>, evaluating inclisiran, dosed twice per year, in patients with atheroslerotic cardiovascular disease and elevated low-density lipoprotein cholesterol (LDL-C) (\"bad\" cholesterol). The data were presented at the American Heart Association Scientific Sessions in Philadelphia.</li><li>The study met the primary endpoints, demonstrating 58% reductions in placebo-adjusted LDL-C levels and 56% reductions in time-averaged placebo-adjusted LDL-C levels from days 90 through 540 (both p levels were &lt;0.0001). Key secondary endpoints were also met.</li><li>Inclisiran's safety profile was similar to control.</li><li>Inclisiran is an investigational GalNAc-conjugated RNAi therapeutic targeting PCSK9, a protein regulator of LDL receptor metabolism. In contrast to PCSK9 inhibitors (like Amgen's (NASDAQ:<a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a>) Repatha and Regeneron (NASDAQ:<a href='https://seekingalpha.com/symbol/REGN' title='Regeneron Pharmaceuticals, Inc.'>REGN</a>) and Sanofi's (NASDAQ:<a href='https://seekingalpha.com/symbol/SNY' title='Sanofi'>SNY</a>) Praluent), PCSK9si works by turning off PCSK9 synthesis in the liver. MDCO is collaborating with Alnylam Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ALNY' title='Alnylam Pharmaceuticals, Inc.'>ALNY</a>) on development under a 2013 agreement.</li><li>The company expects to file a U.S. marketing application this quarter followed by an application in Europe in Q1 2020.</li><li>Data from ORION-9 will be presented today.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520048\" data-linked=\"The Medicines Company up 2% premarket on positive inclisiran data\" data-tweet=\"$MDCO $ALNY $MDCO - The Medicines Company up 2% premarket on positive inclisiran data https://seekingalpha.com/news/3520048-medicines-company-up-2-premarket-on-positive-inclisiran-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3520048-medicines-company-up-2-premarket-on-positive-inclisiran-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520046\" data-ts=\"1574080875\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WRK\" target=\"_blank\">WRK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520046-westrockplus-2-after-baml-bump\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WestRock +2% after BAML bump</a></h4><ul> <li>Bank of America Merrill Lynch lifts WestRock (NYSE:<a href='https://seekingalpha.com/symbol/WRK' title='WestRock Company'>WRK</a>) to a Buy rating after having the packaging stock lined up at Neutral.</li> <li>BAML makes the call after attending two industry events last week.</li> <li>Analyst George Staphos: \"Industry participants are very constructive on its integrated model, combining corrugated and consumer packaging and machinery installations. Taking cost out of customers\u2019 packaging lines is viewed to be an increasingly important factor driving corrugated and WRK\u2019s business model, which marries an in-house machinery/systems capability. These points and WRK\u2019s e-commerce offering were viewed to be important differentiators.\"</li> <li>The firm assigns a price objective of $48 to WestRock vs. the average sell-side PT of <a href=\"https://seekingalpha.com/symbol/WRK/ratings/sell-side-ratings\" target=\"_blank\">$44.14</a>.</li> <li>Shares of WestRock are <font color=\"green\">up 1.86%</font> premarket to $40.70.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3520046\" data-linked=\"WestRock +2% after BAML bump\" data-tweet=\"$WRK - WestRock +2% after BAML bump https://seekingalpha.com/news/3520046-westrockplus-2-after-baml-bump?source=tweet\" data-url=\"https://seekingalpha.com/news/3520046-westrockplus-2-after-baml-bump\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520045\" data-ts=\"1574080803\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OKTA\" target=\"_blank\">OKTA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520045-oktaminus-2-on-valuation-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Okta -2% on valuation downgrade</a></h4><ul><li>Canaccord Genuity cuts Okta (NASDAQ:<a href='https://seekingalpha.com/symbol/OKTA' title='Okta, Inc.'>OKTA</a>) from Buy to Hold, citing a valuation that has the stock \"fully priced\" even if the company has been conservative with its forecasts.</li><li>Analyst Richard Davis says Okta remains the market leader \"by a large margin,\" but the competitive landscape is becoming tighter.</li><li>Price target drops from $145 to $120.</li><li>Okta shares are <font color=\"red\">down 2%</font> pre-market to $115.12.</li><li>The company has a Neutral average <a href=\"https://seekingalpha.com/symbol/OKTA/ratings/quant-ratings\" target=\"_blank\">Quant rating</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520045\" data-linked=\"Okta -2% on valuation downgrade\" data-tweet=\"$OKTA - Okta -2% on valuation downgrade https://seekingalpha.com/news/3520045-oktaminus-2-on-valuation-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3520045-oktaminus-2-on-valuation-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520041\" data-ts=\"1574080640\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QD\" target=\"_blank\">QD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520041-qudian-sinks-5_3-after-year-guidance-revenue-shrinks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Qudian sinks 5.3% after year guidance revenue shrinks</a></h4><ul><li>Qudian (NYSE:<a href='https://seekingalpha.com/symbol/QD' title='Qudian Inc.'>QD</a>)<font color=\"red\"> slides 5.3%</font> after the Chinese online lender cuts its <a href=\"https://seekingalpha.com/pr/17701742-qudian-inc-reports-third-quarter-2019-unaudited-financial-results\" target=\"_blank\">full-year 2019 outlook</a> to reduce its risk-taking loan balance and focus on higher quality borrowers through its open-platform.</li><li>QD now sees RMB 4.0B ($570M) vs. its previous guidance of RMB 4.5B.</li><li>Q3 adjusted non-GAAP net income of RMB 1.06B ($148.6M), or RMB 3.34 (47 cents) per ADS, misses the average analyst estimate of 51 cents per ADS and increases from RMB 694.3M, or RMB 2.17 per ADS, in the year-ago quarter.</li><li>Q3 total revenue of RMB 2.59B ($362.5M) increased 34% Y/Y, primarily due to the ramp up of its open-platform initiative.</li><li>Total number of registered users at Sept. 30, 2019, of 78.3M rose 12% from a year earlier.</li><li>New active borrowers from loan book business and transaction services business increased by 15% to 669,111 in Q3 2019 from 580,727 in Q3 2018.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3520006-qudian-eps-misses-0_04-beats-revenue\" target=\"_blank\">Qudian EPS misses by $0.04, beats on revenue</a> (Nov. 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3520041\" data-linked=\"Qudian sinks 5.3% after year guidance revenue shrinks\" data-tweet=\"$QD - Qudian sinks 5.3% after year guidance revenue shrinks https://seekingalpha.com/news/3520041-qudian-sinks-5_3-after-year-guidance-revenue-shrinks?source=tweet\" data-url=\"https://seekingalpha.com/news/3520041-qudian-sinks-5_3-after-year-guidance-revenue-shrinks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>66&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520036\" data-ts=\"1574080182\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPLK\" target=\"_blank\">SPLK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520036-splunk-boosted-on-fcf-potential-sharesplus-3_4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Splunk boosted on FCF potential; shares +3.4%</a></h4><ul><li>Morgan Stanley leaves the Splunk (NASDAQ:<a href='https://seekingalpha.com/symbol/SPLK' title='Splunk Inc.'>SPLK</a>) sidelines for an Overweight rating. The target is raised from $140 to $169.</li><li>Analyst Keith Weiss sees \"increasing clarity\" in the recurring revenue model shift, which \"likely reveals a durable +25%\" ARR growth story with FCF approaching $1B in FY23.</li><li>SPLK shares are <font color=\"green\">up 3.4%</font><font color=\"green\"> </font>pre-market to $123.28.</li><li>Splunk has a Bullish average <a href=\"https://seekingalpha.com/symbol/SPLK/ratings/sell-side-ratings\" target=\"_blank\">Sell Side rating</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520036\" data-linked=\"Splunk boosted on FCF potential; shares +3.4%\" data-tweet=\"$SPLK - Splunk boosted on FCF potential; shares +3.4% https://seekingalpha.com/news/3520036-splunk-boosted-on-fcf-potential-sharesplus-3_4?source=tweet\" data-url=\"https://seekingalpha.com/news/3520036-splunk-boosted-on-fcf-potential-sharesplus-3_4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:29 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520035\" data-ts=\"1574079885\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KRTX\" target=\"_blank\">KRTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520035-karuna-up-86-premarket-on-positive-karxt-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Karuna up 86% premarket on positive KarXT data</a></h4><ul><li>Thinly traded micro cap Karuna Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/KRTX' title='Karuna Therapeutics, Inc.'>KRTX</a>) is up <font color=\"green\">86% </font>premarket on light volume in reaction to <a href=\"https://seekingalpha.com/pr/17701746-karuna-therapeutics-announces-karxt-met-primary-endpoint-phase-2-clinical-trial-acute\" target=\"_blank\">positive results</a> from a <a href=\"https://clinicaltrials.gov/ct2/show/NCT03697252?lead=karuna&amp;phase=1&amp;draw=2&amp;rank=1\" target=\"_blank\">Phase 2 clinical trial</a> evaluating KarXT in schizophrenia patients with acute psychoses.</li><li>The study met the primary endpoint of a statistically significant change in a scale called PANSS at week 5 compared to placebo. Specifically, participants receiving KarXT showed a mean relative reduction in PANSS score of 11.6 points versus control (p&lt;0.0001). Historically, changes as small as five points have been sufficient for regulatory approval.</li><li>Key secondary endpoints were also met.</li><li>On the safety front, the discontinuation rate was 20% compared to 21% for placebo. Two patients in each arm dropped out due to treatment-emergent adverse events. The most common adverse events were constipation, nausea, dry mouth, dyspepsia (indigestion) and vomiting. 91% of treated patients escalated to the increased dose (similar to placebo).</li><li>KarXT is an orally available combination of xanomeline (a novel muscarinic receptor agonist) and trospium (a muscarinic receptor antagonist). The company says it has the potential to be a new treatment option of debilitating CNS disorders but without the unwanted side effects associated with current antipsychotic medications.</li><li>The company intends to review the data with the FDA in Q2 2020. A Phase 3 trial should launch by the end of 2020.</li><li>Management will host a conference call this morning at 8:30 am ET to discuss the results.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520035\" data-linked=\"Karuna up 86% premarket on positive KarXT data\" data-tweet=\"$KRTX - Karuna up 86% premarket on positive KarXT data https://seekingalpha.com/news/3520035-karuna-up-86-premarket-on-positive-karxt-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3520035-karuna-up-86-premarket-on-positive-karxt-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520034\" data-ts=\"1574079747\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NBY\" target=\"_blank\">NBY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520034-novabay-launches-novasight-daily-vitamin-on-amazon-com-shares-up-21-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NovaBay launches NovaSight daily vitamin on Amazon.com; shares up 21% premarket</a></h4><ul> <li>NovaBay Pharmaceuticals (NYSEMKT:<a href='https://seekingalpha.com/symbol/NBY' title='NovaBay Pharmaceuticals, Inc.'>NBY</a>) is up <font color=\"green\">21%</font> premarket after the <a href=\"https://seekingalpha.com/pr/17701806-novabay-pharmaceuticals-launches-novasight-daily-vitamin-ocular-health-amazon-com\" target=\"_blank\">launch</a> of NovaSight, a proprietary daily vitamin and mineral supplement specially formulated to support ocular health, on Amazon.com.</li><li>NovaSight is a companion product to Avenova Direct, a prescription-strength lid and lash spray available on Amazon.com without a prescription.</li> <li>NovaSight contains 23 active ingredients, more than twice the number as a leading branded eye vitamin and mineral supplement.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3520034\" data-linked=\"NovaBay launches NovaSight daily vitamin on Amazon.com; shares up 21% premarket\" data-tweet=\"$NBY - NovaBay launches NovaSight daily vitamin on Amazon.com; shares up 21% premarket https://seekingalpha.com/news/3520034-novabay-launches-novasight-daily-vitamin-on-amazon-com-shares-up-21-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3520034-novabay-launches-novasight-daily-vitamin-on-amazon-com-shares-up-21-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:22 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520033\" data-ts=\"1574079707\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MANU\" target=\"_blank\">MANU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520033-manchester-unitedplus-3-after-ebitda-improves\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Manchester United +3% after EBITDA improves</a></h4><ul> <li>Manchester United (NYSE:<a href='https://seekingalpha.com/symbol/MANU' title='Manchester United plc'>MANU</a>) tops estimates on flat <a href=\"https://seekingalpha.com/pr/17701834-manchester-united-plc-reports-first-quarter-fiscal-2020-results-reiterates-fiscal-year-2020\" target=\"_blank\">FQ1</a> revenue of £135M.</li> <li>Matchday revenue was up 36% to £22.1M and commercial revenue was 5.9% higher to £80M to help offset a 23% drop in broadcasting revenue during the quarter to £33M. Non-participation in the UEFA Champions League hurt the club's revenue tally during the quarter.</li> <li>Adjusted EBITDA was £34.8M vs. £29.4M a year ago.</li> <li>Looking ahead, the company expects FY20 revenue to fall in a range of £560M to £580M and adjusted EBITDA of £155M to £165M.</li><li>Shares of Manchester United are <font color=\"green\">up 2.58%</font> premarket to $16.65.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3520026-manchester-united-eps-beats-0_06-beats-revenue\" target=\"_blank\">Manchester United EPS beats by £0.06, beats on revenue</a> (Nov. 18)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3520033\" data-linked=\"Manchester United +3% after EBITDA improves\" data-tweet=\"$MANU - Manchester United +3% after EBITDA improves https://seekingalpha.com/news/3520033-manchester-unitedplus-3-after-ebitda-improves?source=tweet\" data-url=\"https://seekingalpha.com/news/3520033-manchester-unitedplus-3-after-ebitda-improves\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:21 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520031\" data-ts=\"1574079468\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ESTC\" target=\"_blank\">ESTC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520031-elasticplus-3_7-canaccord-turns-bullish\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Elastic +3.7% as Canaccord turns bullish</a></h4><ul><li>Canaccord Genuity upgrades Elastic (NYSE:<a href='https://seekingalpha.com/symbol/ESTC' title='Elastic N.V.'>ESTC</a>) from Hold to Buy with a $90 price target. The company has a Bullish average <a href=\"https://seekingalpha.com/symbol/ESTC/ratings/sell-side-ratings\" target=\"_blank\">Sell Side rating</a>.</li><li>The firm cites ESTC's \"promising long-term prospects\" and thinks the company could increase revenue 10-fold within the next 7-10 years.</li><li>Canaccord says valuation became more reasonable after the 30% decline from a July peak.</li><li>Elastic shares are <font color=\"green\">up 3.7%</font> pre-market to $77.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520031\" data-linked=\"Elastic +3.7% as Canaccord turns bullish\" data-tweet=\"$ESTC - Elastic +3.7% as Canaccord turns bullish https://seekingalpha.com/news/3520031-elasticplus-3_7-canaccord-turns-bullish?source=tweet\" data-url=\"https://seekingalpha.com/news/3520031-elasticplus-3_7-canaccord-turns-bullish\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520030\" data-ts=\"1574079430\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPWR\" target=\"_blank\">SPWR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520030-sunpower-launches-22m-share-public-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SunPower launches 22M-share public offering</a></h4><ul><li>SunPower (NASDAQ:<a href='https://seekingalpha.com/symbol/SPWR' title='SunPower Corporation'>SPWR</a>) <font color=\"red\">-7.2%</font> pre-market after announcing plans for a 22M-share <a href=\"https://seekingalpha.com/pr/17701858-sunpower-announces-public-offering-common-stock\" target=\"_blank\">public offering</a>, with an underwriters' option for an additional 3.3M common shares.</li><li>SPWR says it plans to use the net proceeds for general corporate purposes, which may include partially funding the repayment of its 0.875% senior convertible debentures due 2021.</li><li>The offering would increase SPWR's shares outstanding by ~15%.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520030\" data-linked=\"SunPower launches 22M-share public offering\" data-tweet=\"$SPWR - SunPower launches 22M-share public offering https://seekingalpha.com/news/3520030-sunpower-launches-22m-share-public-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3520030-sunpower-launches-22m-share-public-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520028\" data-ts=\"1574079317\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PHIO\" target=\"_blank\">PHIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520028-phio-pharma-down-37-premarket-on-pricing-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Phio Pharma down 37% premarket on pricing equity offering</a></h4><ul> <li>Phio Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/PHIO' title='Phio Pharmaceuticals Corp.'>PHIO</a>) <a href=\"https://seekingalpha.com/pr/17701854-phio-pharmaceuticals-announces-pricing-1_0-million-public-offering-common-stock\" target=\"_blank\">prices</a> its public offering of 10M common shares at $0.10/share, for gross proceeds of $1M.</li>  <li>Net proceeds will be used to fund the development of its immuno-oncology programs, for other R&amp;D activities and for general working capital needs.</li><li>Closing date is November 19.</li><li>Shares are down <font color=\"red\">37%</font> premarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3518913-phio-pharma-launches-equity-offering\" target=\"_blank\">Phio Pharma launches equity offering</a> (Nov. 13)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3520028\" data-linked=\"Phio Pharma down 37% premarket on pricing equity offering\" data-tweet=\"$PHIO - Phio Pharma down 37% premarket on pricing equity offering https://seekingalpha.com/news/3520028-phio-pharma-down-37-premarket-on-pricing-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3520028-phio-pharma-down-37-premarket-on-pricing-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:15 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520025\" data-ts=\"1574078756\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLX\" target=\"_blank\">PLX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520025-protalix-bioplus-25-premarket-on-successfully-completing-pre-bla-meeting-for-accelerated\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Protalix Bio +25% premarket on successfully completing pre-BLA meeting for accelerated approval of PRX\u2011102</a></h4><ul><li>Protalix BioTherapeutics (NYSEMKT:<a href='https://seekingalpha.com/symbol/PLX' title='Protalix BioTherapeutics, Inc.'>PLX</a>) and its development partner, Chiesi Farmaceutici S.p.A., have <a href=\"https://seekingalpha.com/pr/17701804-protalix-biotherapeutics-chiesi-farmaceutici-announce-successful-pre-bla-meeting-fda\" target=\"_blank\">completed</a> a successful Type B Pre-BLA meeting with the FDA regarding the Accelerated Approval pathway for pegunigalsidase alfa (PRX\u2011102) for the treatment of Fabry disease.</li><li>The BLA will include data from the Company's completed phase I/II clinical trials of pegunigalsidase alfa and from its ongoing phase III BRIDGE clinical trial.</li><li>The BLA is expected to be submitted by April 2020. The FDA indicated that no additional clinical trials will be required for the proposed BLA submission.</li><li>If approved, PLX will be eligible to receive a milestone payment from Chiesi.</li><li>Shares are up <font color=\"green\">25%</font> premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520025\" data-linked=\"Protalix Bio +25% premarket on successfully completing pre-BLA meeting for accelerated approval of PRX\u2011102\" data-tweet=\"$PLX - Protalix Bio +25% premarket on successfully completing pre-BLA meeting for accelerated approval of PRX\u2011102 https://seekingalpha.com/news/3520025-protalix-bioplus-25-premarket-on-successfully-completing-pre-bla-meeting-for-accelerated?source=tweet\" data-url=\"https://seekingalpha.com/news/3520025-protalix-bioplus-25-premarket-on-successfully-completing-pre-bla-meeting-for-accelerated\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520016\" data-ts=\"1574077294\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EWU\" target=\"_blank\">EWU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520016-sterling-rallies-tories-unite-behind-brexit-plan\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sterling rallies as Tories unite behind Brexit plan</a></h4><ul><li>The pound <font color=\"green\">jumped 0.5%</font> to $1.2967 overnight after Boris Johnson <a href=\"https://www.bloomberg.com/news/articles/2019-11-18/pound-gains-as-traders-dare-to-believe-brexit-deadlock-will-end\" target=\"_blank\">said</a> every Conservative candidate has signed a pledge to vote for his Brexit deal if elected next month.</li><li>Opinion polls that showed the Tories in the lead further helped propel sterling <font color=\"green\">up 0.8%</font> over the past week, as a withdrawal agreement would remove some of Brexit uncertainty.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/EWU' title='iShares MSCI United Kingdom ETF'>EWU</a>, <a href='https://seekingalpha.com/symbol/FXB' title='Invesco CurrencyShares British Pound Sterling Trust ETF'>FXB</a>, <a href='https://seekingalpha.com/symbol/GBB' title='iPath GBP/USD Exchange Rate ETN'>OTC:GBB</a>, <a href='https://seekingalpha.com/symbol/EWUS' title='iShares Trust - iShares MSCI United Kingdom Small-Cap ETF'>EWUS</a>, <a href='https://seekingalpha.com/symbol/FKU' title='First Trust United Kingdom AlphaDex ETF'>FKU</a>, <a href='https://seekingalpha.com/symbol/DGBP' title='VelocityShares Daily 4X Long USD vs. GBP ETN'>DGBP</a>, <a href='https://seekingalpha.com/symbol/HEWU' title='iShares Currency Hedged MSCI United Kingdom ETF'>HEWU</a>, <a href='https://seekingalpha.com/symbol/FLGB' title='Franklin Templeton ETF Trust - Franklin FTSE United Kingdom ETF'>FLGB</a>, <a href='https://seekingalpha.com/symbol/UGBP' title='VelocityShares Daily 4X Long GBP vs. USD ETN'>UGBP</a>, <a href='https://seekingalpha.com/symbol/ZGBR' title='SPDR Index Shares Funds - SPDR Solactive United Kingdom ETF'>ZGBR</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3520016\" data-linked=\"Sterling rallies as Tories unite behind Brexit plan\" data-tweet=\"$EWU $FXB $GBB - Sterling rallies as Tories unite behind Brexit plan https://seekingalpha.com/news/3520016-sterling-rallies-tories-unite-behind-brexit-plan?source=tweet\" data-url=\"https://seekingalpha.com/news/3520016-sterling-rallies-tories-unite-behind-brexit-plan\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}